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Ancestry Study Citation(s) T2D Case Ascertainment T2D Control Ascertainment T1D and MODY exclusion criteria Genotyping array
European Finland-United States Investigation of 
NIDDM Genetics (FUSION) Study
Valle, T. et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study. Diabetes Care 21(6), 949-958 (1998); Scott, L. et al. A genome-wide association study of type 2 
diabetes in Finns detects multiple susceptibility variants. Science 316(5829), 1341-1345 (2007)
- Unrelated cases selected from FUSION families and stage 2 replication
- Samples met 1999 World Health Organization (WHO) criteria of fasting plasma 
glucose ≥7.0 mmol/l or postload glucose during an OGTT ≥11.1 mmol/l, by report of 
diabetes medication use, or based on medical record review
- Prioritized FUSION families with ≥2 first-degree relatives with T2D; BMI 
≥18.5kg/m2; case with GWAS data or earliest age at onset, if no GWAS data 
available
- Prioritized FUSION stage 2 replication set with Metabochip data; BMI ≥18.5kg/m2; 
earliest age of onset; age of onset ≥35 
- Unrelated controls with normal glucose tolerance (NGT) based on WHO (1999) definitions: 
fasting plasma glucose <6.1 mM and 2 hour postload glucose during an OGTT <7.8 mM
- Frequency matched to cases by birth province; BMI ≥18.5kg/m2; age ≤80
- Within each birth province, prioritized samples from stage 2 replication with highest values for 
age + 2*BMI
- When possible, we prioritized cases with 
age of diagnosis between 35 and 60, 
without history of insulin-dependent 
diabetes among first degree relatives, with 
at least one full sibling diagnosed with T2D, 
and with at least one parent who was 
apparently nondiabetic.
Illumina 317K, HumanOmniExpress-
12v1, and HumanExome-12v1_A
European Kooperative Gesundheitsforschung in der 
Region Augsburg (KORA)
Wichmann, H. E., Gieger, C. and Illig, T. KORA-gen–resource for population genetics, controls and a broad 
spectrum of disease phenotypes. Gesundheitswesen 67 Suppl 1, 26–30 (2005)
Holle R, Happich M, Löwel H, Wichmann HE, MONICA/KORA Study Group. KORA - a research platform for 
population based health research. Gesundheitswesen. 2005 Aug; 67 Suppl 1:S19-25.
PMID: 16032513
- Samples drawn from KORA F3 and F4
- Diabetic status validated by doctor or by medication use
Prioritized cases with ≥1 first-degree relative with T2D (self-reported).- Cases have 
≥1 first degree relative with type 2 diabetes (self-reported)
- Cases have either BMI ≤30 and age of onset <65, or BMI ≤33 and age of onset ≤60
- Controls selected from KORA F4
- All controls are normal glucose tolerant: fasting glucose level <6.1 mmol/l and two hour 
glucose level after oral glucose tolerance test <7.8 mmol/l
- Controls are either >60 years of age with BMI >32 or over 65 years of age with BMI >31
- None applied Illumina HumanOmniExpress-12v1, 
Illumina HumanOmni2.5-8, Affymetrix 
Axiom array
European UK Type 2 Diabetes Genetics Consortium 
(UKT2D)
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature 447, 661–78 (2007); Voight, B.F. et al. Twelve type 2 diabetes 
susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579–589 (2010); Spector, T.D. 
and Williams, F.M. The UK Adult Twin Registry (TwinsUK). Twin Res. Hum. Genet. 9, 899–906 (2006)
- Cases drawn from the Wellcome Trust Case Control Consortium (WTCCC)
- Female samples with age of diagnosis ≥66 years or BMI ≥32kg/m2 excluded; male 
samples with age of diagnosis ≥62 years or BMI ≥31kg/m2 excluded
- Remaining samples were ranked by age and BMI, and the two ranks multiplied.
- Unrelated samples selected as controls from the Twins UK study
- A twin pair was considered for selection if there was no recorded family history of diabetes, 
neither twin was ever recorded as impaired glucose tolerant (defined as fasting glucose 
>6.1mmol/L in any reading), there were available quantitative trait and genetic (GWAs) data, and 
no evidence of admixture in MDS analysis of GWAs data
- From set of qualifying twin pairs, the best control twin was selected from each pair with the 
lowest ratio of fasting glucose level to BMI across all readings, and further prioritization of the 
qualifying unrelated samples involved selecting samples that had the lowest fasting glucose to 
(BMI * age) ratios
- Top two principal components were used to perform pairwise sample matching between cases 
and possible controls, and the best control for each case was selected
- Cases having a first degree relative with 
type 1 diabetes; testing positive for GAD 
antibodies; or known to have other forms of 
diabetes, such as MODY, excluded
- Controls having a first degree relative with 
type 1 diabetes excluded
Affymetrix GeneChip Human Mapping 
500K Array Set (cases) and Illumina 
317K (controls)
European Malmo-Botnia Study Guey LT et al. Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare 
variants. Genet Epidemiol 35, 236–46 (2011); Groop, L. et al. Metabolic consequences of a family history of NIDDM 
(the Botnia study): evidence for sex-specific parental effects. Diabetes 45, 1585–93 (1996); Parker, A. et al. A gene 
conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes 
50, 675–80 (2001); Lyssenko, V. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. 
NEJM 359, 2220–32 (2008); Lindholm, E., Agardh, E., Tuomi, T., Groop, L. & Agardh, C. D. Classifying diabetes 
according to the new WHO clinical stages. Eur. J. of Epid. 17, 983–9 (2001); Berglund, G. et al. Long-term outcome 
of the Malmo Preventive Project: Mortality and cardiovascular morbidity. J. of Intern. Med. 247, 19–29 (2000)
- A liability score was generated (Guey LT et al. 2011) which measures risk to T2D in 
the context of three known risk factors (age at onset, BMI, and gender) in 27,500 
individuals drawn from three prospective cohorts: the Malmö Preventive Project, the 
Scania Diabetes Registry, and the Botnia Study; only BMI and gender used to 
construct scores for Scania and Botnia studies
- Early-onset cases with low BMI and older controls with high BMI were prioritized
- Controls selected from the extreme of a liability score distribution, based upon gender, age and 
BMI at last follow-up visit; only BMI and gender used to construct scores for Malmö study
- To match for ethnicity, equal numbers of controls were selected from the Botnia and Malmö 
studies
- Diabetic individuals with age of onset <35 
years excluded
Illumina HumanOmniExpress-12v1
Supplementary Table 1a | Whole genome sequence cohort information
Cases Controls
Ancestry Study N Total N Case # Females (%) Mean age (SD), 
years
Mean BMI (SD), 
kg/m2
N Control # Females (%) Mean age (SD), 
years
Mean BMI (SD), 
kg/m2
European Finland-United States Investigation of NIDDM Genetics (FUSION) Study 979 493 41.5 57.6 (7.9) 30.9 (5.6) 486 45.2 63.0 (7.2) 28.0 (3.9)
European Kooperative Gesundheitsforschung in der Region Augsburg (KORA) 205 101 44.5 61.4 (8.2) 28.2 (2.8) 104 66.3 69.6 (5.6) 34.4 (3.5)
European Malmo-Botnia Study 829 410 51.5 53.8 (9.7) 24.2 (2.6) 419 44.1 67.2 (7.7) 32.8 (4.0)
European UK Type 2 Diabetes Genetics Consortium (UKT2D) 644 322 46.2 50.1 (8.4) 26.6 (2.7) 322 82.2 60.6 (10.0) 30.5 (5.8)
Supplementary Table 1b | Whole genome sequence sample characteristics
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Supplementary Table 2 | Single-variant T2D association analysis descriptions 
Dataset Statistical Test Covariates Imputation Sample-size meta Inverse variance meta Quality filter 
GoT2D sequenced Score Firth Age, sex, before/after association*, PC1, PC2 N/A 
GoT2D imputed      
  DGDG Score Score Age, gender, PC1, PC2 INFO>0.4 
  DGI Score Firth Age, sex, BMI, 3 indicators (Malmo, Helsinki, 
Skara) 
INFO>0.4 
  EGCUT 370K LRT LRT Age, sex, PC1 – PC10 INFO>0.4 
  EGCUT OMNI LRT LRT Age, sex, PC1 – PC10 INFO>0.4 
  FHS (MAF>0.01 only) GEE (Wald) GEE (Wald) AGE, SEX, cohort, PC1 – PC10 INFO>0.4 
  FUSION Score Firth Age (continuous), sex, 12 birth provinces RSQ>0.3 
  INTERACT Score Score Sex, PC1 – PC10 INFO>0.4 
  KORA Score Score Age, sex, PC1 – PC3 INFO>0.4 
  MSSMIPM (Affymetrix) Score (MAC≥200) Score (MAC≥200) Age, sex, PC1 – PC5 INFO>0.4 Firth (MAC<200) Firth (MAC<200) 
  MSSMIPM (Illumina) Score (MAC≥200) Score (MAC≥200) Age, sex, PC1 – PC4 INFO>0.4 Firth (MAC<200) Firth (MAC<200) 
  PIVUS Score Score Age, sex, PC1, PC2 INFO>0.4 
  ULSAM Score Score PC1, PC2 (all males, same age) INFO>0.4 
  WTCCC Score Score  INFO>0.4 
LRT Likelihood ratio test, GEE Generalized estimating equations. 
*Indicator function to account for observed temporal stratification based on sequencing date and center. 
Ancestry Study Citation(s) T2D Case Ascertainment T2D Control Ascertainment T1D and MODY exclusion criteria Genotyping array
 European MT. SINAI BioMe Biobank Platform (BioMe (Affy)) Gottesman O, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, 
present and future. Genet. Med. 15,761-771  (2013)
- From longitudinal EMR:  random glucose ≥ 200 mg/dl ever, or physician-entered diagnosis (≥2 
occurrences on 2 separate days), or T2D medication (≥2 occurrences on 2 separate days)
- Age ≥ 25 years 
- Age ≥25 years
- Not having T2D
- All available fasting glucose measurements <100 mg/dl
- Age ≥ 25 years Affymetrix 6.0
 European MT. SINAI BioMe Biobank Platform (BioMe (Illumina)) Gottesman O, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, 
present and future. Genet. Med. 15,761-771  (2013)
- From longitudinal EMR:  random glucose ≥ 200 mg/dl ever, or physician-entered diagnosis (≥2 
occurrences on 2 separate days), or T2D medication (≥2 occurrences on 2 separate days)
- Age ≥ 25 years 
- Age ≥25 years
- Not having T2D
- All available fasting glucose measurements <100 mg/dl
- Age ≥ 25 years Illumina OMNI ExpressExome
 European Diabetes Gene Discovery Group (DGDG) Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. 
Nature 445, 881-885 (2007)
-  1997 American Diabetes Association (ADA) criteria
-  Family history of diabetes in first-degree relatives
-  BMI<30 kg/m²
- Age at examination >45 years
- Normal fasting glucose according to 1997 ADA criteria: FG <5.7 mmol/l
- BMI <27 kg/m²
- Cases with age of diagnosis <45 years were 
screened for known MODY mutations
- Cases from the Corbeil-Essonnes Hospital 
tested for fasting C-peptide levels; if fasting C-
peptide<0.4 mg/l, subjects tested for anti-GAD 
antibodies; those with anti-GAD antibodies 
>10U/ml excluded. 
- 29% of cases from UMR8090 CNRS tested for 
anti-islet-antibodies and/or anti-insulin antibodies; 
positive cases excluded
Illumina Human Hap 300 Bead Array
 European Diabetes Genetics Initiative (DGI) Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis 
Institutes of BioMedical Research , et al.  Genome-Wide Association Analysis Identifies Loci for 
Type 2 Diabetes and Triglyceride Levels. Science 316,1331-1336 (2007)
- WHO (1999) criteria with fasting glucose ≥7.0 mmol/l or 2-hour glucose ≥11.1 mmol/l during an oral 
glucose tolerance test. 
- Age of diagnosis >35 years
- No first-degree relatives with T2D - Anti-GAD antibodies <32 IU/ml in the Finnish 
samples and <1.3 anti-GAD relative units in the 
Swedish samples                                                                    
- Age of diagnosis >35 years
Affymetrix GeneChip Human Mapping 500k Array Set
 European Estonian Genome Center, University of Tartu (EGCUT-
OMNI)
Leitsalu L, et al.  Cohort profile: Estonian Biobank of the Estonian genome Center, University of 
Tartu.  Int. J. Epidemiol. 44, 1137-1147 (2014)
- Standardized health examination together with questionnaires on health-related topics as 
described in WHO ICD-10. Data are regularly updated through linkage to national databases and 
registries.
- Random subset of the Estonian population -None applied Illumina OmniExpress Array
 European Estonian Genome Center, University of Tartu (EGCUT-
370)
Leitsalu L, et al.  Cohort profile: Estonian Biobank of the Estonian genome Center, University of 
Tartu.  Int. J. Epidemiol. 44, 1137-1147 (2014)
- Standardized health examination together with questionnaires on health-related topics as 
described in WHO ICD-10. Data are regularly updated through linkage to national databases and 
registries.
- Random subset of the Estonian population -None applied Illumina HumanHap 370K Array
 European Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study
Scott, L. J. et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects 
multiple susceptibility variants. Science 316, 1341-1345 (2007)
- WHO 1999 criteria of FG≥7.0 mmol/l or 2-hour plasma glucose ≥11.1 mmol/l or reported diabetes 
medication use or based on medical record review
- NGT as defined by WHO 1999 criteria - No known or probable type 1 diabetes among 
first degree relatives                                                                   
'-Insulin treatment initiated within 10 years of 
disease
diagnosis, detectable levels of anti-GAD 
antibodies and fasting C-peptide ≤0.30 nmol/l                                 
'- Insulin treatment initiated within 4 years of 
diagnosis and fasting C-peptide ≤0.30 nmol/l
Illumina Human Hap 300 Bead Array
 European InterAct Langenberg, C  Design and cohort description of the InterAct Project: an examination of the 
interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. 
Diabetlogia 54, 2272-2282 (2011)
- Self-report (self-reported history of T2D, doctor-diagnosed T2D, diabetes drug use) and linkage to 
primary care registers, secondary care registers, medication use (drug registers), hospital 
admissions, and mortality data, using information from any follow-up visit or external evidence with a 
date later than the baseline visit.                                                                                 -In Sweden, 
cases ascertained via local and national diabetes and pharmaceutical registers.                                                                                       
-Centers outside Sweden required evidence of T2D from ≥2 independent sources, including 
individual medical records review at some centers. 
- Individuals without T2D -None applied Illumina HumanHap 660 Array
 European KORAgen Study Helmholtz zentrum München (KORA) Wichmann HE, Gieger C, Illig T  MONICA/KORA Study Group.  Gesundheitswesen 67 Suppl 1, 
S26-30. Review (2005)
- Self-report in personal interview validated by a questionnaire mailed to the treating physician 
and/or by medical chart review
-
- Non-diabetic by self-report -None applied Affymetrix GeneChip Human Mapping 500k Array Set
 European Prospective Investigation of the Vasculature in Uppsala 
Seniors (PIVUS)
Lind, L. et al.  A comparison of three different methods to evaluate endothelium-dependent 
vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors 
(PIVUS) study. Arterioscler. Thromb. Vasc. Biol.  25, 2368-2375 (2005)
- Fasting blood glucose >6.1 mmol/l or known diabetes - Individuals without T2D -None applied Illumina Metabochip and Illumina OmniExpress Array. 
 European Uppsala Longitudinal Study of Adult Men (ULSAM) Ingelsson E, et al. Insulin resistance and risk of congestive heart failure.  JAMA 294, 334-341 
(2005)
- Hospital discharge register-defined diabetes before 2002. - Individuals without T2D -None applied Illumina Metabochip and Illumina OmniExpress Array. 
 European Welcome Trust Case Control Consortium (WTCCC) Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale replication 
identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40, 638-645 (2008)
- Current prescribed treatment with oral agents and/or insulin, or, for individuals treated with diet 
alone, laboratory evidence of hyperglycemia as defined by WHO
- All cases were diagnosed between ages 25 and 75 years.
- Selected without reference to T2D status
- 1958 Birth Cohort controls of self-reported white ethnicity and 
representative of gender and each geographical region
- UK blood donor controls selected based on sex and geographical region 
to reproduce the distribution of the samples of the 1958 Birth Cohort
- Age of diagnosis ≥25                                                                                                                          
- Absence of first-degree relatives with T1D                             
- Individuals with other known forms of diabetes 
were excluded 
- ≥ 1 year between diagnosis and institution of 
regular insulin therapy
- Negative testing for anti-GAD antibodies
Affymetrix Human Mapping 500K Array
Supplementary Table 3a | Imputed cohort information
Dawber, TR et al.  Epidemiological approaches to heart disease: the Framingham Study. Am. J. 
Public Health Nations Health 41, 279-281 (1951); Feinleib, M et al. The Framingham Offspring 
Study. Design and preliminary data. Prev. Med. 4, 518-525 (1975); Splansky, GL et al. The 
Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart 
Study: design, recruitment, and initial examination. Am. J. Epidemiol.165,1328-1335  (2007)  
-None applied Affymetrix GeneChip Human Mapping 500k Array Set + 
MIPS 50K
 European Framingham Heart Study (FHS) - Gen 1 cohort: casual glucose ≥200 mg/dl or taking diabetes medication at any examination
- Gen 2 cohort (offspring): FG≥126 mg/dl or diabetes treatment at any examination
- Gen 3 cohort: fasting glucose ≥126 mg/dl or diabetes treatment at examination
- Fasting glucose <126 mg/dl and no T2D medication at the most recent 
study visit
Cases Controls
Ancestry Study N Total N Case # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2 Mean age of diagnosis 
(SD), years
N Control # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2
European Diabetes Gene Discovery Group (DGDG) 1374 677 266  (39.3) 59.5 (10.0) 26.1 (2.7) 45.4(8.3) 697 416 (59.7) 53.5 (5.7) 23.2 (1.8)
European Diabetes Genetics Initiative (DGI) 1956 899 419  (46.6) 65.3 (9.9) 28.1 (4.1) 59.2 (10.1) 1057 533 (49.6) 58.3 (9.6) 26.7 (3.7)
European Estonian Genome Center, University of Tartu (EGCUT-370) 1848 80 39 (48.8) 61.9 (11.3) 31.6 (4.8) NA 1768 902   (51.0) 39.7 (16.1) 25.7 (5.1)
European Estonian Genome Center, University of Tartu (EGCUT-OMNI) 6402 389 228 (58.6) 70.2 (11.8) 31.1 (6.2) NA 6013 3259 (54.2) 50.9 (20.4) 26.5 (5.1)
European Framingham Heart Study (FHS) 8333 673 287 (42.6) 63.7 (12.4) 31.4 (6.5) NA 7660 4219 (55.1) 52.3 (16.0) 27.0 (5.1)
European Finland United States Investigation of NIDDM (FUSION) Study 2150 1060 457 (43.1) 63.0 (7.6) 30.3 (4.7) NA 1090 560 (51.3) 63.2 (7.4) 26.9 (3.7)
European INTERACT 9292 4624 2395 (51.8) NA 30.0 (4.8) NA 4668 2995 (64.2) NA 25.9 (4.2)
European KORAgen Study Helmholtz zentrum München (KORA) 3978 993 447(45.1) 60.4 (11.0) 31.0 (5.4) NA 2985 1558 (52.2) 55.6 (13.2) 27.3 (4.5)
European MT. SINAI BioMe Biobank Platform (BioMe (Affy)) 587 132 35 (26.5) 66.0 (10.7) 31.3 (6.3) NA 455 158  (34.7) 66.0(10.7) 26.5 (5.2)
European MT. SINAI BioMe Biobank Platform (BioMe (Illumina)) 1902 255 74 (29.0) 69.1 (9.0) 30.7 (6.2) NA 1647 846 (51.4) 69.1 (9.0) 26.3 (5.0)
European Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 949 111 46 (41.4) 70.2 (0.1) 29.1 (5.3) NA 838 492 (51.2) 70.2 (0.2) 26.8 (4.2)
European Uppsala Longitudinal Study of Adult Men (ULSAM) 1119 166 0 71.0 (0.7) 27.9 (3.9) NA 953 0 71.0(0.6) 26.0(3.2)
European Welcome Trust Case Control Consortium (WTCCC) 4524 1586 649 (40.9) 58.3 (10.1) 32.2 (6.2)   49.0 (11.9) 2938 1492 (50.8) 43.3 (12.3) 28.2 (4.3)
Supplementary Table 3b | Imputed cohort sample characteristics
Ancestry Study Citation(s) T2D Case Ascertainment T2D Control Ascertainment T1D and MODY exclusion criteria Genotyping array
African American Jackson Heart Study (AJ) Taylor, H. A. et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods 
of the Jackson Heart Study. Ethn Dis 15, S6–4 (2005)
- Genomic DNA from blood and genome-wide genotypes available (minimum 25 ug 
DNA remaining)
- Non-related individuals based on family IDs
- ADA 2004 definition of T2D diagnosed either of two exams
- No T2D by ADA 2004 definition, fasting plasma glucose <100 mg/dl, and HbA1c <6% at each 
of two exams
- Controls were matched to cases in a two-stage approach:
1. Strong matches (greedy algorithm): age > 50, sex match, BMI within 1 unit, and age within 5 
years (N=457 matched pairs)
2. Closest available matches: sex match and BMI > 25; for females, BMI within 5 units and age 
within 20 years; for males, BMI within 8 units and age within 25 years (N=117 matched pairs)
- Samples with age of onset <16 years and 
treated only with insulin were excluded
Affymetrix Genome-Wide Human 
SNP Array 6.0
African American Wake Forest School of Medicine Study 
(AW)
Palmer, N. D. et al. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One 
7:e29202. (2012)
- Cases are self-reported diabetics with diabetic nephropathy, recruited from dialysis 
clinics
- Age of onset ≥25
- Individuals excluded if at any point after diagnosis treatment consisted of insulin 
therapy alone
- Additionally, at least one of the following three criteria met for inclusion: a) T2D 
diagnosed at least 5 years before initiating renal replacement therapy, b) 
background or greater diabetic retinopathy, and c) ≥100 mg/dl proteinuria on 
urinalysis in the absence of other causes of nephropathy
- No current diagnosis of diabetes or renal disease
- Individuals recruited from community and internal medicine clinics
- Type 1 diabetes is uncommon in African 
Americans, so no ICA tests have been 
performed
- Age of onset ≥25
- Individuals excluded if at any point after 
diagnosis treatment consisted of insulin 
therapy alone
Affymetrix Genome-Wide Human 
SNP Array 6.0
East Asian Korea Association Research Project 
[Korean] (EK)
Cho, Y. S. et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors 
influencing eight quantitative traits. Nat. Genet. 41, 527–534 (2009)
- Past history of T2D
- Use of T2D medication 
- Fasting plasma glucose ≥7 mmol/l or plasma glucose ≥11.1 mmol/l 2 hours after 
ingestion of 75gm oral glucose load
- Age of disease onset ≥40 years
- Participants with early onset and family history prioritized
- No past history of diabetes 
- No anti-diabetic medication
- Fasting plasma glucose <5.6 mmol/l and plasma glucose 2 hours after ingestion of 75g oral 
glucose load <7.8 mmol/l at both baseline and follow up timepoints
- Older subjects with normal glucose prioritized
- Samples with age of diagnosis <40 
excluded
Affymetrix Genome-Wide Human 
SNP Array 5.0
East Asian Singapore Diabetes Cohort Study and 
Singapore Prospective Study Program 
[Singapore Chinese] (ES)
Sim, X. et al. Transferability of type 2 diabetes implicated loci in multi-ethnic cohorts from Southeast Asia. PLoS 
Genet. 7(4), e1001363 (2011)
- Clinically ascertained T2D from primary care clinics
- Individuals with early age of diagnosis and with at least one first degree relative 
with T2D were preferentially selected
- Fasting blood glucose <6 mmol/l  
- No personal history of diabetes 
- No anti-diabetic medication
- Older controls preferentially selected
- Clinical records were extracted from 
primary care clinics, and suspected T1D and 
MODY cases were excluded
Illumina Human610-Quad BeadChip / 
Illumina Human1M-Duo v3.0
European Ashkenazi (UA) Atzmon, G. et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol. 
4(4), e113 (2006); Atzmon, G. et al. Evolution in health and medicine Sackler colloquium: Genetic variation in 
human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A. 107 
(Suppl 1), 1710-1717 (2010); Permutt, M.A. et al. A genome scan for type 2 diabetes susceptibility loci in a 
genetically isolated population. Diabetes 50(3), 681-685 (2001); Blech et al. Predicting diabetic nephropathy using a 
multifactorial genetic model. PLoS One 6(4), e18743 (2011)
- Ashkenazi Jewish origin, defined as having all four grandparents born in Northern 
or Eastern Europe; subjects with known or supected Sephardic Jewish or non-
Jewish ancestry excluded
- T2D defined according to the World Health Organisation criteria (fasting glucose 
>140 mg/dl on two or more ocasions or random glucose >200mg/dl)
- To avoid late-onset T1D, patients who became insulin-dependent within 2 years of 
diagnosis excluded; anti-GAD or anti-islet cell antibody titers not routinely measured
- T2D cases were selected from two separate DNA collections: 
1. Genome-wide, affected-sibling-pair linkage study (Permutt et al. Diabetes 2001). 
Families in which both parents were known to have diabetes were excluded. One 
affected individual  selected from each family and, wherever possible, sibling with 
youngest age of diagnosis selected. 
2. Study to determine genetic risk for diabetic complications (Blech et al. PLoS One 
2011). Patients ascertained by the Israel Diabetes Research Group between 2002 
and 2004 from 15 diabetes clinics throughout Israel. Primary selection criteria: (1) 
known T1D or T2D for more than 10 years, (2) 4 grandparents being either 
Ashkenazi or Sephardic-North African Jewish. For this study, only T2D patients with 
all 4 grandparents of Ashkenazi Jewish origin and age of diagnosis between 35 and 
60 were selected.                                                                         
- Fasting blood glucose <7 mmol/l 
- No personal history of diabetes
- No anti-diabetic medications
- Patients who became insulin-dependent 
within 2 years of diagnosis excluded
Illumina Cardio-Metabo Chip
European Metabolic Syndrome in Men Study [Finnish] 
(UM)
Stancakova, A. et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance 
in 6,414 Finnish men. Diabetes 58, 1212–1221 (2009)
- Previous diagnosis of T2D, or both fasting and 2-hr criteria met for new T2D 
diagnosis
- C-peptide >0.10 nmol/L                                                                              
- Anti-GAD antibody <50 U/mL to rule out T1D                                                                                   
- Family history of diabetes (parents, sibs, children, grandparents, avuncular, 
cousins)
- Unrelated individuals based on family ID and IBS analyses
- Preferentially select individuals with with genotype data (N=494), as well as non-
genotyped individuals with earlier possible age of diagnosis (N=26)
- Normal glucose tolerance at baseline and follow-up visits
- Prioritized samples with no family history of diabetes and meeting strict NGT criteria: fasting 
glucose <5.6 mmol/l and 2 hour post-challenge glucose <7.8 mmol/l
- Additional samples selected with fasting glucose <6.1 mmol/l and 2 hour post-challenge 
glucose <7.8 mmol/l
- Unrelated samples
- Older controls preferentially selected
- C-peptide <0.10 nmol/L                                                                              
- Anti-GAD antibody >50 U/mL
Illumina Cardio-Metabo Chip and 
HumanOmniExpress-12v1
European Finland-United States Investigation of 
NIDDM Genetics (FUSION) Study [Finnish]
Valle, T. et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics 
(FUSION) Study. Diabetes Care 21(6), 949-958 (1998); Scott, L. et al. A genome-wide association study of type 2 
diabetes in Finns detects multiple susceptibility variants. Science 316(5829), 1341-1345 (2007)
- Unrelated cases selected from FUSION families and stage 2 replication
- Samples met 1999 World Health Organization (WHO) criteria of fasting plasma 
glucose ≥7.0 mmol/l or postload glucose during an OGTT ≥11.1 mmol/l, by report of 
diabetes medication use, or based on medical record review
- Prioritized FUSION families with ≥2 first-degree relatives with T2D; BMI 
≥18.5kg/m2; case with GWAS data or earliest age at onset, if no GWAS data 
available
- Prioritized FUSION stage 2 replication set with Metabochip data; BMI ≥18.5kg/m2; 
earliest age of onset; age of onset ≥35 
- Unrelated controls with normal glucose tolerance (NGT) based on WHO (1999) definitions: 
fasting plasma glucose <6.1 mM and 2 hour postload glucose during an OGTT <7.8 mM
- Frequency matched to cases by birth province; BMI ≥18.5kg/m2; age ≤80
- Within each birth province, prioritized samples from stage 2 replication with highest values for 
age + 2*BMI
- When possible, we prioritized cases with 
age of diagnosis between 35 and 60, 
without history of insulin-dependent 
diabetes among first degree relatives, with 
at least one full sibling diagnosed with T2D, 
and with at least one parent who was 
apparently nondiabetic.
Illumina 317K, HumanOmniExpress-
12v1, and HumanExome-12v1_A
European KORA [German] Wichmann, H. E., Gieger, C. and Illig, T. KORA-gen–resource for population genetics, controls and a broad 
spectrum of disease phenotypes. Gesundheitswesen 67 Suppl 1, 26–30 (2005)
Holle R, Happich M, Löwel H, Wichmann HE, MONICA/KORA Study Group. KORA - a research platform for 
population based health research. Gesundheitswesen. 2005 Aug; 67 Suppl 1:S19-25.
PMID: 16032513
- Samples drawn from KORA F3 and F4
- Diabetic status validated by doctor or by medication use
- Cases have ≥1 first degree relative with type 2 diabetes (self-reported)
- Cases have either BMI ≤30 and age of onset <65, or BMI ≤33 and age of onset 
≤60
- Controls selected from KORA F4
- All controls are normal glucose tolerant: fasting glucose level <6.1 mmol/l and two hour 
glucose level after oral glucose tolerance test <7.8 mmol/l
- Controls are either >60 years of age with BMI >32 or over 65 years of age with BMI >31
- None applied Illumina HumanOmniExpress-12v1, 
Illumina HumanOmni2.5-8, Affymetrix 
Axiom array
European UKT2D Consortium Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature 447, 661–78 (2007); Voight, B.F. et al. Twelve type 2 diabetes 
susceptibility loci identified through large-scale association analysis. Nat. Genet. 42, 579–589 (2010); Spector, T.D. 
and Williams, F.M. The UK Adult Twin Registry (TwinsUK). Twin Res. Hum. Genet. 9, 899–906 (2006)
- Cases drawn from the Wellcome Trust Case Control Consortium (WTCCC)
- Female samples with age of diagnosis ≥66 years or BMI ≥32kg/m2 excluded; male 
samples with age of diagnosis ≥62 years or BMI ≥31kg/m2 excluded
- Remaining samples were ranked by age and BMI, and the two ranks multiplied. 
356 samples with the lowest values for this rank multiplier were selected for initial 
inclusion in the study
- Unrelated samples selected as controls from the Twins UK study
- A twin pair was considered for selection if there was no recorded family history of diabetes, 
neither twin was ever recorded as impaired glucose tolerant (defined as fasting glucose 
>6.1mmol/L in any reading), there were available quantitative trait and genetic (GWAs) data, and 
no evidence of admixture in MDS analysis of GWAs data
- From set of qualifying twin pairs, the best control twin was selected from each pair with the 
lowest ratio of fasting glucose level to BMI across all readings, and further prioritization of the 
qualifying unrelated samples involved selecting samples that had the lowest fasting glucose to 
(BMI * age) ratios
- Top two principal components were used to perform pairwise sample matching between cases 
and possible controls, and the best control for each case was selected
- Cases having a first degree relative with 
type 1 diabetes; testing positive for GAD 
antibodies; or known to have other forms of 
diabetes, such as MODY, excluded
- Controls having a first degree relative with 
type 1 diabetes excluded
Affymetrix GeneChip Human Mapping 
500K Array Set (cases) and Illumina 
317K (controls)
Supplementary Table 4a | Exome sequence cohort information
European Malmo-Botnia Study [Finnish, Swedish] Guey LT et al. Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare 
variants. Genet Epidemiol 35, 236–46 (2011); Groop, L. et al. Metabolic consequences of a family history of NIDDM 
(the Botnia study): evidence for sex-specific parental effects. Diabetes 45, 1585–93 (1996); Parker, A. et al. A gene 
conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes 
50, 675–80 (2001); Lyssenko, V. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. 
NEJM 359, 2220–32 (2008); Lindholm, E., Agardh, E., Tuomi, T., Groop, L. & Agardh, C. D. Classifying diabetes 
according to the new WHO clinical stages. Eur. J. of Epid. 17, 983–9 (2001); Berglund, G. et al. Long-term outcome 
of the Malmo Preventive Project: Mortality and cardiovascular morbidity. J. of Intern. Med. 247, 19–29 (2000)
- A liability score was generated (Guey LT et al. 2011) which measures risk to T2D in 
the context of three known risk factors (age at onset, BMI, and gender) in 27,500 
individuals drawn from three prospective cohorts: the Malmö Preventive Project, the 
Scania Diabetes Registry, and the Botnia Study; only BMI and gender used to 
construct scores for Scania and Botnia studies
- Eligible cases limited to individuals between 35 and 60 years of age and with a BMI 
between 20 and 35
- To match for ethnicity, 250 Botnia cases with the most extreme liability scores were 
selected, while 125 cases were selected from each of the Scania and Malmö studies
- Controls selected from the extreme of a liability score distribution, based upon gender, age and 
BMI at last follow-up visit; only BMI and gender used to construct scores for Malmö study
- Eligible controls limited to individuals above 35 years of age at follow-up and with a BMI 
between 20 and 40
- To match for ethnicity, equal numbers of controls were selected from the Botnia and Malmö 
studies
- Diabetic individuals with age of onset <35 
years excluded
Illumina HumanOmniExpress-12v1
Hispanic San Antonio Mexican American Family 
Studies: San Antonio Family Heart Study, 
San Antonio Family Diabetes/Gallbladder 
Study, Veterans Administration Genetic 
Epidemiology Study, and Family 
Investigation of Nephropathy and Diabetes 
Study - San Antonio  Component (HA)
Mitchell, B. D. et al. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. 
The San Antonio Family Heart Study. Circulation 94, 2159–2170 (1996); Hunt, K. J. et al. Genome-wide linkage 
analyses of type 2 diabetes in Mexican Americans: the San Antonio Family Diabetes/Gallbladder Study. Diabetes 
54, 2655–2662 (2005); Coletta, D. K. et al. Genome-wide linkage scan for genes influencing plasma triglyceride 
levels in the Veterans Administration Genetic Epidemiology Study. Diabetes 58, 279–284 (2009); Knowler, W. C. et 
al. The Family Investigation of Nephropathy and Diabetes (FIND): design and methods. J. Diabetes Complicat. 19, 
1–9 (2005)
- Unrelated and non-overlapping individuals/samples drawn from four separate 
family studies, San Antonio, TX
- Cases met one or more of four criteria:
1. American Diabetes Association [ADA] criterion (2002) -- fasting plasma glucose 
≥126 mg/dl
2. World Health Organization [WHO] criteria (1999) -- fasting plasma glucose ≥126 
mg/dl or a 2 hour glucose tolerance test ≥200 mg/dl 
3. Self-reported physician-diagnosed diabetes and self-reported current therapy with 
either oral antidiabetic agents or insulin                                                                       
4. Had hemoglobin A1c (HbA1c) ≥7.0%
- No self-reported antidiabetic therapy at any visit, including oral agents or insulin prescribed as 
a result of physician-diagnosed diabetes AND one or more of the following:                                                            
1. Fasting glucose <126 mg/dl at each visit
2. If OGTT performed, 2 hour glucose must be <200 mg/dl     
3. No history of diabetes and HbA1c <6.0%, or HbA1c 6.0-6.9% and fasting glucose <126 mg/dl                        
Samples prioritized with strict NGT with no family history first, then NGT in two visits, followed by 
oldest age        
- None applied Illumina Cardio-Metabo Chip
Hispanic Starr County, Texas (HS) Hanis, C. L. et al. Diabetes among Mexican Americans in Starr County, Texas. Am. J. Epidemiol. 118, 659–672 
(1983); Below JE, et al. Genome-wide association and meta-analysis in populations from Starr County, Texas and 
Mexico City identify type 2 diabetes susceptibility loci and enrichment for eQTLs in top signals. Diabetologia 54, 
2047-2055 (2011)
- Diagnosis of diabetes according to National Diabetes Data Group (1979) 
guidelines drawn from several studies in Starr County:
1. Fasting glucose ≥ 140 mg/dl on more than 1 occasion
2. Self-reported physician-diagnosed diabetes and self reported therapy with either 
oral antidiabetic agents or insulin (either currently or for more than one month in the 
past)
- In instances where cases were drawn from families, the individual with youngest 
age at onset was chosen
- Controls ascertained from epidemiologically represented sample of individuals in Starr County, 
TX
- Individuals with known diagnosis of diabetes excluded
- Impaired glucose tolerant and impaired fasting glucose controls retained due to the age 
difference between cases and controls (controls are younger on average) and to allow sufficient 
sample size
- Cases with age of onset <35 and BMI<30 
excluded as potential T1D or MODY
Affymetrix Genome-Wide Human 
SNP Array 6.0
South Asian London Life Sciences Population Study 
[UK Indian Asians] (SL)
Chambers, J.C. et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin 
levels. Nat. Genet. 41, 1170-1172 (2009); Chambers, J.C. et al. Common genetic variation near melatonin receptor 
MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and 
European Caucasians. Diabetes 58, 2703-2708 (2009); van der Harst, P. et al. Seventy-five genetic loci influencing 
the human red blood cell. Nature 492, 369-375 (2012)
- Samples chosen from a population-based cohort study
- Indian Asians living in West London, UK with all 4 grandparents born on the Indian 
subcontinent
- Prevalent T2D defined as previous physician diagnosis of diabetes on treatment, 
with onset of diabetes after the age of 18 years and without insulin use in the first 
year after diagnosis; or fasting plasma glucose ≥7.0 mmol/L
- No previous history of diabetes
- No anti-diabetic medication
- Fasting plasma glucose <6.0 mmol/L
- Samples with age of onset <18 excluded Illumina Human610-Quad BeadChip
South Asian Singapore Indian Eye Study [Singapore 
Indians] (SS)
Sim, X. et al. Transferability of type 2 diabetes implicated loci in multi-ethnic cohorts from Southeast Asia. PLoS 
Genet. 7(4), e1001363 (2011)
- HbA1c ≥6.5% or personal history of diabetes with age at diagnosis available
- Preferentially selected cases with at least one first degree relative with T2D
- HbA1c <6%
- No personal history of diabetes
- Not taking antidiabetes medication
- Older controls preferentially selected
- None applied Illumina Human610-Quad BeadChip
Cases Controls
Ancestry Study N Total N Case # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2 Mean age of diagnosis 
(SD), years
N Control # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2
1026 500 333 (66.6) F: 58.1 (10.0) F: 34.5 (6.8) F: 49.1 (11.2) 526 333 (63.3) F: 55.8 (11.4) F: 33 (6.8)
M: 57.9 (11.2) M: 31 (4.7) M: 49.3 (11.0) M: 56.4 (11.2) M: 30 (5.1)
1048 518 308 (59.5) F: 64.8 (9.3) F: 30.3 (7.1) F: 46.9 (10.0) 530 297 (56.0) F: 50.7 (12.2) F: 31.5 (7.3)
M: 62.3 (8.7) M: 27.9 (5.3) M: 47.6 (9.6) M: 51.4 (10.8) M: 28 (6.0)
1087 526 240 (45.6) F: 55.4 (7.2) F: 26.3 (3.4) F: NA 561 328 (58.5) F: 62.9 (3.5) F: 24.2 (3.1)
M: 52.5 (7.4) M: 25.2 (3.0) M: NA M: 63.8 (3.6) M: 23.1 (2.8)
1078 486 253 (52.1) F: 58.7 (9.9) F: 25.6 (3.9) F: 45.5 (9.0) 592 363 (61.3) F: 58.1 (6.7) F: 22.8 (3.4)
M: 57.3 (8.7) M: 25.6 (3.7) M: 44.2 (9.4) M: 58.5 (7.5) M: 23 (3.3)
861 506 238 (47) F: 65.9 (8.7) F: 27.6 (3.2) F: 49 (5.5) 355 202 (56.9) F: 80.1 (14.5) F: 24.4 (4.3)
M: 65.6 (8.6) M: 27.2 (3.1) M: 47.7 (5.3) M: 76.7 (11.5) M: 26.3 (3.7)
982 484 0 (0) F: NA F: NA F: NA 498 0 (0) F: NA F: NA
M: 60.4 (6.7) M: 30.6 (5.1) M: 54.6 (8.5) M: 54.7 (4.5) M: 25.8 (3.1)
948 472 201 (42.6) F: 58.6 (9.0) F: 31.3 (5.6) F: NA 476 214 (45.0) F: 63.8 (7.1) F: 28.5 (4.4)
M: 56.9 (7.1) M: 30.5 (5.5) M: NA M: 62.2 (7.3) M: 27.5 (3.3)
187 97 43 (44.3) F: 60.6 (8.8) F: 28.9 (2.8) F: NA 90 57 (63.3) F: 68.9 (5.4) F: 34.6 (3.5)
M: 61.9 (7.6) M: 27.9 (2.8) M: NA M: 70.9 (5.8) M: 34.2 (3.4)
642 322 147 (45.7) F: 51.2 (9.1) F: 27.1 (2.7) F: NA 320 265 (82.8) F: 60.9 (10.2) F: 31 (6.2)
M: 48.9 (7.7) M: 26.4 (2.7) M: NA M: 59.8 (9.0) M: 28.4 (3.7)
921 478 262 (54.8) F: 56.8 (10.1) F: 24.8 (2.8) F: 47.4 (7.7) 443 194 (43.8) F: 68 (8.0) F: 33.7 (4.1)
M: 52.5 (10.2) M: 23.9 (2.2) M: 45.6 (7.2) M: 65.6 (8.1) M: 32.2 (3.9)
490 272 160 (58.8) F: 58 (13.3) F: 32.9 (6.9) F: 45.5 (14.7) 218 128 (58.7) F: 53.3 (15.2) F: 31.1 (7.3)
M: 57.7 (11.0) M: 31.6 (7.7) M: 44.5 (14.4) M: 50.9 (14.6) M: 28.9 (6.1)
1453 749 447 (59.7) F: 56 (11.9) F: 32.9 (6.8) F: 46 (11.0) 704 506 (71.9) F: 39.1 (9.4) F: 30.4 (6.5)
M: 56.9 (11.8) M: 30.2 (5.3) M: 47.7 (11.0) M: 39.4 (11.1) M: 29.5 (5.3)
1069 531 75 (14.1) F: 53.4 (5.5) F: 27.7 (3.0) F: NA 538 85 (15.8) F: 63.6 (8.9) F: 28.2 (4.4)
M: 52.7 (5.7) M: 26.5 (2.8) M: NA M: 63.4 (9.2) M: 27 (3.3)
1148 563 250 (44.4) F: 59.8 (9.4) F: 28.2 (6.0) F: 50.5 (10.7) 585 288 (49.2) F: 55.8 (9.7) F: 26.3 (5.6)
M: 61.6 (9.9) M: 25.9 (4.0) M: 50.9 (10.5) M: 56.4 (10.4) M: 24.4 (3.5)
Supplementary Table 4b |  Exome sequence sample characteristics
Jackson Heart Study (AJ)African American
African American Wake Forest School of Medicine Study (AW)
Korea Association Research Project [Korean] (EK)East Asian
East Asian Singapore Diabetes Cohort Study and Singapore Prospective Study 
Program [Singapore Chinese] (ES)
Ashkenazi (UA)European
European Metabolic Syndrome in Men Study [Finnish] (UM)
Finland-United States Investigation of NIDDM Genetics (FUSION) Study 
[Finnish]
European
European KORA [German]
UKT2D ConsortiumEuropean
London Life Sciences Population Study [UK Indian Asians] (SL)South Asian
South Asian Singapore Indian Eye Study [Singapore Indians] (SS)
European Malmo-Botnia Study [Finnish, Swedish]
San Antonio Mexican American Family Studies: San Antonio Family Heart 
Study, San Antonio Family Diabetes/Gallbladder Study, Veterans 
Administration Genetic Epidemiology Study, and Family Investigation of 
Nephropathy and Diabetes Study - San Antonio  Component (HA)
Hispanic
Hispanic Starr County, Texas (HS)
Supplementary Figure 5 | Quality control of 12,940 WES samples. To assess the sequencing 
quality of each sample, we computed multiple statistics stratified by sample ethnicity. We then 
identified outlier samples relative to any of the statistical distributions and excluded them from 
further analysis. Shown are the distributions for nine representative statistics after samples were 
removed from analysis; note that these metrics are computed prior to any variant quality control 
and thus measure different statistics than presented in other display items. Number of variants: 
the number of variants (biallelic or multiallelic SNPs and INDELs) at which the sample exome 
carries a minor allele. Number of biallelic SNPs: the number of biallelic SNPs at which the sample 
exome carries a minor allele. Number of biallelic indels: the number of biallelic INDELs at which 
the sample exome carries a minor allele. Number of singletons: the number of variants carried by 
the sample alone (e.g., at which all other samples have the reference genotype). Heterozygosity: 
the heterozygosity of the sample computed across all variant sites. Heterozygosity at low 
frequency variants: the heterozygosity of the sample computed across low-frequency (MAF < 1%) 
variant sites. Heterozygous:Homozygous ratio: the ratio of heterozygous non-reference alleles to 
homozygous non-reference alleles in the sample. Mean allele balance: the fraction of sequence 
reads containing the non-reference allele, averaged over all heterozygous sites in the sample. 
Mean allele balance at singleton sites: the fraction of sequence reads containing the non-
reference allele, averaged over all singleton heterozygous sites in the sample. 
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Supplementary Figure 6 | Quality control of INDELs. To assess the quality of called INDEL 
variants, we computed two metrics. (a) The number of INDELs with size equal to x (mod 3), for 
various values of x. Negative values represent deletions, while positive values represent insertions. 
As frameshift variants are more likely to disrupt protein sequence than in-frame deletions, spikes at 
increments of three are expected for INDEL variants in the population. (bc) Principal component 
analysis of the 12,940 European samples, computed using common (MAF > 1%) (b) SNPs and 
INDELs and (c) INDELs only. If the majority of common SNPs and INDELs are of high quality, the 
principal components should be concordant between the two analyses. 
a Length distribution of indels
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Principal component analysis (SNPs and INDELs)
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Supplementary Table 7 | Per individual variant counts by ethnic group
QC+ variants
All	  samples African-­‐American East-­‐Asian European Hispanic South-­‐Asian
Samples: 12,940 2,074 2,165 4,541 1,943 2,217
Variants:
Synonymous	  SNP 9243	  [8423;11487] 10910	  [9857;11487] 8837	  [8559;9258] 8851	  [8427;9264] 9024	  [8595;9428] 9070	  [8423;9387]
Missense	  SNP 7636	  [6935;9271] 8885	  [8038;9271] 7348	  [7042;8133] 7341	  [6939;7933] 7468	  [7069;8155] 7499	  [6935;7885]
Start	  SNP* 11	  [4;22] 12	  [5;22] 9	  [4;16] 11	  [4;18] 11	  [5;18] 11	  [5;20]
Nonsense	  SNP* 62	  [37;93] 69	  [50;93] 60	  [40;82] 60	  [37;84] 61	  [45;93] 60	  [44;81]
Frameshift	  INDEL* 137	  [115;182] 147	  [124;172] 137	  [120;160] 134	  [115;155] 136	  [118;182] 136	  [117;156]
Inframe	  INDEL 76	  [56;111] 89	  [70;111] 72	  [60;90] 72	  [56;91] 75	  [58;92] 75	  [59;91]
3'UTR	  SNP,	  INDEL 532	  [449;700] 633	  [548;700] 513	  [465;589] 506	  [449;567] 516	  [461;578] 523	  [474;576]
5'UTR	  SNP,	  INDEL 864	  [747;1119] 1021	  [903;1119] 836	  [783;895] 824	  [747;904] 843	  [781;942] 848	  [769;924]
Intron	  SNP,	  INDEL 13110	  [11477;16462] 15590	  [13917;16462] 12540	  [12119;13972] 12510	  [11989;13611] 12810	  [12159;14405] 12830	  [11477;13357]
Essential	  splicing	  SNP,	  INDEL* 40	  [27;61] 46	  [30;61] 42	  [30;55] 38	  [27;55] 40	  [27;56] 39	  [28;56]
Other	  splicing	  SNP,	  INDEL 1586	  [1411;2022] 1886	  [1675;2022] 1531	  [1455;1652] 1514	  [1411;1614] 1543	  [1426;1641] 1547	  [1417;1644]
Non-­‐coding	  RNA	  SNP,	  INDEL 245	  [192;337] 288	  [241;337] 232	  [192;266] 236	  [196;290] 238	  [199;277] 239	  [193;283]
All	  variants 34070	  [30901;41971] 40330	  [36180;41971] 32640	  [31659;35250] 32570	  [31079;35021] 33280	  [31666;36390] 33390	  [30901;34590]
All	  Biallelic	  SNPs 31770	  [28811;38933] 37490	  [33674;38933] 30460	  [29534;32871] 30400	  [29014;32652] 31040	  [29585;33864] 31150	  [28811;32262]
All	  Biallelic	  INDELs 265	  [171;597] 452	  [299;597] 230	  [187;305] 217	  [171;299] 247	  [199;366] 239	  [191;309]
All	  Multiallelics 2036	  [1821;2565] 2383	  [2140;2565] 1948	  [1844;2255] 1958	  [1837;2265] 1991	  [1849;2281] 1999	  [1821;2169]
*	  Protein	  truncating
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Supplementary Table 9A | Distribution of mean age-of-diagnosis by PAX4 Arg192His (rs2233580) 
genotypes in replication studies. 
 
Study No. of cases 
Age of diagnosis (years) 
[Mean ± SD] 𝜷(SE) p-valuea 
CC CT TT 
SNUH 570 50.81 ± 9.67 51.61 ± 11.52 51.20 ± 10.90 0.66 0.458 
Hong-Kong 489 36.41 ± 9.49 36.80 ± 10.13 32.14 ± 6.58 0.70 0.351 
Singapore 560 57.12 ± 12.55 56.47 ± 13.03 52.40 ± 12.18 -1.26 0.232 
Combined 1,619    0.24 0.640 𝛽: Regression coefficient estimates. SE: standard error 
a Linear regression p-value of age-of- diagnosis with Arg192His 
 
 
Supplementary Table 9B | Single-variant T2D association analysis of PAX4 Arg192His (rs2233580) in 
each ancestry group from exome-sequence analysis and replication. 
 
 Genotype counts 
(CC/TC/TT) 
Odds ratio 
(95% CI) 
p-value 
Ancestral group Cases Controls   
Within ancestry analysis 
African American 1018 / 0 / 0 1056 / 0 / 0 - - 
East Asian 779 / 201 / 32 981 / 167 / 5 1.79 [1.47-2.19] 9.26x10-9 
European 2359 / 0 / 0 2182 / 0 / 0 - - 
Hispanic 1021 / 0 / 0 921 / 1 / 0 - - 
South Asian 1093 / 1 / 0 1122 / 1 / 0 - - 
Meta-analysis - - 1.79 [1.47-2.19] 9.26x10-9 
Replication studies 
SNUH 500 / 107 / 15 390 / 43 / 8 1.62 (1.20 – 2.19) 0.00186 
Hong-Kong 315 / 153 / 22 260 / 80 / 3 1.76 (1.33 – 2.32) 6.81x10-5 
Singapore 504 / 157 / 16 568 / 147 / 10 1.24 (0.99 – 1.54) 0.0588 
Meta-analysis - - 1.47 (1.26 – 1.70) 5.87x10-7 
 
 
Supplementary Table 9C | Study information 
 
Ancestry Study Citation(s) PubMed 
ID(s) 
T2D Case 
Ascertainment 
T2D Control 
Ascertainment 
T1D and MODY 
exclusion criteria 
Genotyping 
and QC 
East Asian Hong Kong Diabetes 
Registry + Using 
resequencing and 
bioinformatics to discover a 
genomic signatory to predict 
young onset and familial type 
2 diabetes [Hong Kong 
Chinese] 
Ma RC, et al. Genome-wide 
association study in a Chinese 
population identifies a 
susceptibility locus for type 2 
diabetes at 7q32 near PAX4. 
Diabetologia 2013; 56(6): 
1291-305. 
23532257  - Clinically diagnosed 
with T2D 
 - Cases with early onset 
diabetes were 
preferentially selected 
 - Fasting blood glucose < 
6.1 mmol/l 
 - No history of diabetes 
 - BMI ≤ 25 
 - No central obesity 
 - Cases with T1D 
presentation were 
excluded 
 - Cases need insulin 
within 1 year of diagnosis 
were excluded 
Sanger 
Sequencing 
Call Rate = 0.99 
HWE P = 0.806 
East Asian Seoul National University 
Hospital Diabetes Case 
Control Study [Korean] 
Cho, Y. S. et al. Meta-analysis 
of genome-wide association 
studies identifies eight new loci 
for type 2 diabetes in east 
Asians. Nat Genet. 
11;44(1):67-72 (2011) 
22158537  - Clinically diagnosed as 
T2D using World Health 
Organization criteria 
 - Participants with at 
least one sibling with 
T2D were preferentially 
included 
- Age ≥ 60 years old 
- No previous history of 
diabetes 
- No family history of 
diabetes in first degree 
relatives 
- Fasting plasma glucose < 
6.1 mmol/l 
- HbA1c < 5.8% 
- Diabetes patients 
positive for GAD 
antibodies were excluded 
- Diabetes patients with 
onset before age of 25 or 
suspected MODY cases 
were excluded 
TaqMan 
genotyping 
Call rate =0.997  
HWE P =2.0e-4 
(re-sequencing 
confirms 
genotype calls 
of minor allele 
homozygotes) 
East Asian Singapore Diabetes Cohort 
Study and Singapore 
Prospective Study Program 
[Singapore Chinese] 
Sim, X. et al. Transferability of 
type 2 diabetes implicated loci 
in multi-ethnic cohorts from 
Southeast Asia. PLoS Genet. 
7(4), e1001363 (2011) 
21490949 - Clinically ascertained 
T2D from primary care 
clinics 
- Fasting blood glucose <6 
mmol/l   
- No personal history of 
diabetes  
- No anti-diabetic 
medication 
- Clinical records were 
extracted from primary 
care clinics, and 
suspected T1D and MODY 
cases were excluded 
Illumina 
Human1M-Duo 
v3.0 
Call rate = 1.00 
HWE P = 0.86 
 
Supplementary Table 9D | Sample characteristics 
   Cases         Controls       
Ancestry Study N Total N Case # Females 
(%) 
Mean age 
(SD), years 
Mean BMI 
(SD), kg/m2 
Mean age of 
diagnosis 
(SD), years 
N Control # Females 
(%) 
Mean age 
(SD), years 
Mean BMI 
(SD), kg/m2 
East Asian Hong Kong Diabetes Registry + 
Using resequencing and 
bioinformatics to discover a 
genomic signatory to predict 
young onset and familial type 2 
diabetes [Hong Kong Chinese] 
833 490 274 (55.9) F: 43.5 (11.4) F: 25.0 (4.2) F: 34.7 (8.8) 343 183 (52.7) F: 43.3 (9.0) F: 22.9 (3.9) 
M: 46.6 (12.3) M: 24.8 (4.1) M: 38.4 
(10.2) 
M: 43.9 (10.5) M: 23.9 (3.1) 
East Asian Seoul National University Hospital 
Diabetes Case Control Study 
[Korean] 
1063 622 344 (55.3) 
F:60.6 (9.6) F: 24.6 (4.4) F: 51.4 (9.5) 
441 248 (56.2) 
F: 64.4 (3.1) F: 24.0 (3.3) 
M: 59.9 (10.0) M: 24.1 (3.3) M: 50.4 (10.7) M: 65.2 (3.8) M: 22.5 (3.6) 
East Asian Singapore Diabetes Cohort Study 
and Singapore Prospective Study 
Program [Singapore Chinese] 1402 677 232(16.5) 
F: 65.6(10.3) F: 25.4(4.2) F: 57.1(12.9) 
725 281(20.0) 
42.1(7.1) 21.9(3.5) 
M: 66.3(9.9) M: 25.2(3.6) M:56.7(12.6) 44.2(8.8) 23.4(3.2) 
 
Supplementary Table 10 | Summary of biological knowledge for genes described in the paper 
Gene Biological function Previously disease association Mouse knockout model 
ABCC8 
"ATP-binding cassette sub-family C member 8". Member of the superfamily of 
ATP-binding cassette (ABC) transporters, which modulates ATP-sensitive 
potassium channels and insulin release from beta cells. Receptor for sulfonylurea 
antidiabetic agents (SUR1). 
T2D (OMIM 125853). Leucine-sensitive hypoglycemia of 
infancy (OMIM 240800). Familial hyperinsulinemic 
hypoglycemia 1 (OMIM 256450). Transient neonatal 
diabetes mellitus type 2 (OMIM 610374). Permanent 
neonatal diabetes mellitus (OMIM 606176). 
Adult mice are glucose intolerant with reduced 
glucose-stimulated insulin secretion from isolated 
islets (PMID 10734066). 
COBLL1 "Cordon-bleu protein-like 1". Contains two WH2 (Wiskott-Aldrich homology 2) actin binding domains. 
T2D (PMID 23160641). Metabolic Syndrome (PMID 
24981077). Lower fasting insulin and lower insulin resistance 
in obese children (PMID 23463496). BMI-adjusted waist-hip-
ratio in women (PMID 23754948). 
No knockout reported. 
FES 
"Tyrosine-protein kinase Fes/Fps". Cytoplasmic protein tyrosine kinase implicated 
in the regulation of the actin cytoskeleton and myeloid differentiation. Promotes 
survival of leukemia cells and is present as an activated kinase in some patients 
with acute myeloid leukemia. 
Feline sarcoma (Fes) / Fujinami avian sarcoma (Fps) viral 
oncogene homolog (OMIM 190030). 
No metabolic phenotypes identified. Knockouts show 
partial lethality and runting. Adults have abnormal 
hematopoiesis and leukocyte function (PMID 
11021537). 
GCKR 
“Glucokinase (hexokinase 4) regulator”. Member of Sugar Isomerase (SIS) family 
of proteins that forms a complex with and inhibits glucokinase in liver and possibly 
pancreatic beta cells and neurons. 
T2D (OMIM 125853). Serum glucose and insulin-related 
traits (PMID 20081858). Serum triglycerides (PMID 
18193043) and LDL cholesterol (PMID 18179892). Plasma 
C-reactive protein (PMID 18439548). 
Reduced hepatic glucokinase expression and activity. 
Altered glucose and insulin homeostasis worsened by 
high-sucrose diet (PMID 10588736). 
GPSM1 
"G-protein-signaling modulator 1". Receptor-independent activator of basal G-
protein signaling. Inhibits GDP-dissociation from Galpha(i). Associated SNP 
affects a putative interaction site for STK11/LKB1 
T2D (PMID 23945395). 
Reduced body weight and white adipose tissue mass. 
Increased food consumption and increased nocturnal 
energy expenditure. Altered blood pressure 
homeostasis (PMID 18450958). 
GRB14 
“Growth factor receptor-bound protein 14” Adapter protein containing SH2, ras-
associating and pleckstrin homology domains, involved in receptor kinase 
singalling. Negative regulator of insulin receptor activation of ERK1/2 (PMID 
11726652). Promotes PDPK1 recruitment to activated insulin receptor and 
subsequent PKB/AKT activation (PMID 15210700). 
T2D (PMID 21874001). Metabolic Syndrome (PMID 
24981077) 
Decreased body weight. Improved glucose tolerance. 
Reduced circulating insulin levels. Increased signaling 
through IRS-1 and PKB in liver and skeletal muscle 
(PMID 14749734). 
HNF1A "Hepatocyte nuclear factor 1-alpha". Transcription factor regulating expression of tissue-specific genes in hepatocytes and islet and exocrine cells of the pancreas. 
T2D (OMIM 125853, OMIM 612520). Maturity-onset diabetes 
of the young type 3 (OMIM 600496). 
Reduced serum insulin and increased serum glucose 
levels. Decreased linear growth with GH resistance. 
Hepatic steatosis with abnormal liver function (PMID 
9566924, PMID 8598044). 
HNF4A 
"Hepatocyte nuclear factor 4-alpha". Nuclear receptor involved in regulation of 
liver-specific transcripts, including genes involved in gluconeogenesis and fat 
metabolism (PMID 23485969). 
T2D (OMIM 125853). Maturity-onset diabetes of the young 
type 1 (OMIM 125850). 
knockout shows premature death (by early adulthood) 
with abnormal liver morphology and function. Isoform-
specific knockouts show impaired glucose tolerance 
(HNF4alpha1) and dyslipidemia (HNF4alpha7) (PMID 
11158324, PMID 16498401). 
KCNJ11 
"ATP-sensitive inward rectifier potassium channel 11". Potassium inwardly-
rectifying channel. Activity regulated by G-proteins. Provides channel pore whose 
activity is regulated by the sulfonylurea receptor ABCC8/SUR1 in the beta-cell 
ATP-sensitive potassium channel. 
T2D (OMIM 125853). Familial hyperinsulinemic 
hypoglycemia type 2 (OMIM 601820). Transient neonatal 
diabetes mellitus type 3 (OMIM 610582). Permanent 
neonatal diabetes mellitus (OMIM 606176). 
Metabolic phenotypes include impaired insulin 
secretion and mild glucose intolerance. Reduced 
glucagon secretion in response to hypoglycemia. 
Increased energy expenditure with reduced 
susceptibility to diet-induced obesity (PMID 
11319559, PMID 20074528). 
MTMR3 
"Myotubularin-related protein 3". Myotubularin dual specificity protein 
phosphatase. Phosphatase can hydrolyze phosphatidylinositol 3-phosphate, 
phosphatidylinositol 3,5-bisphosphate and other phosphoinositide lipids. 
LDL cholesterol (PMID 24097068). Lung cancer (PMID 
21725308). Early-onset inflammatory bowel disease (PMID 
19915574): IgA nephropathy (PMID 21725308). 
Impaired glucose tolerance (males). Increased serum 
alkaline phosphatase (both sexes only) (JAX 
J103485). 
PAM 
"Peptidyl-glycine alpha-amidating monooxygenase". Catalyzes C-terminal alpha-
amidation of peptides, which is required for full bioactivity of some neuropeptides 
and peptide hormones. Variant alters intragranular domain in NHL2 repeat of 
peptidyl-alpha-hydroxyglycine alpha-amidating lyase region. 
T2D (PMID 24464100). Insulinogenic index (PMID 
23263489). 
Knockout mice die in mid-gestation (e14.5-e15.5). Old 
heterozygotes (age >10 months) have mild glucose 
intolerance and increased white fat mass (PMID 
16225857). 
PAX4 
"Paired box protein Pax-4". Transcriptional repressor containing homeobox 
domain that binds to a common element in the glucagon, insulin and somatostatin 
promoters. Critical roles during fetal pancreatic islet development and 
differentiation of insulin producing beta cells. Variant alters highly conserved 
amino acid in homeodomain region (Arg192His) and is predicted to be deleterious 
by some scores. Located in the GCC1 locus identified by T2D GWA Studies. 
T2D (OMIM 125853). Maturity-onset diabetes of the young 
type 9 (OMIM 612225). Ketosis-prone Diabetes Mellitus 
(PMID 612227). 
Knockout mice show early postnatal lethality (within 
3d of birth). Pancreatic islets lack cells expressing 
insulin and somatostatin and contain cells expressing 
ghrelin, glucagon and islet amyloid polypeptide (PMID 
18058910). 
PPARG 
"Peroxisome proliferator-activated receptor gamma". Nuclear receptor activated by 
peroxisome proliferators including hypolipidemic drugs and fatty acids. Key 
transcriptional regulator of adipocyte differentiation. Controls expression of the 
peroxisomal beta-oxidation pathway of fatty acids. 
T2D (OMIM 125853). Obesity (OMIM 601665). Carotid 
intimal medial thickness 1 (OMIM 609338). Familial partial 
lipodystrophy type 3 (OMIM 604367). 
Adipose-specific PPARG knockout shows diminished 
levels of leptin and adiponectin. PPARG liver 
knockout shows lower cholesterol, FFA, TG. (PMID 
10549291, PMID 15070754, PMID 10675354). 
PPIP5K2 
"Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2". 
Bifunctional inositol kinase that acts with the IP6K kinases to synthesize 
diphosphate group-containing inositol pyrophosphates including diphosphoinositol 
pentakisphosphate. Regulates a variety of cellular processes including vesicle 
trafficking, exocytosis, insulin signaling and apoptosis. 
No disease associations. No knockout reported. 
RREB1 
"Ras-responsive element-binding protein 1". Krueppel C2H2-type zinc-finger 
protein that binds specifically to the RAS-responsive elements of gene promoters. 
Variant alters a conserved residue (Asp1171Asn) predicted to be deleterious by 
some algorithms. 
Body fat distribution (PMID 23966867). Serum urate levels 
(PMID 20884846). No knockout reported. 
SLC30A8 
“Solute carrier family 30 member 8”. Zinc efflux transporter involved in the 
accumulation of zinc in intracellular vesicles. Colocalizes with insulin in the 
secretory pathway granules of insulin-secreting cells. Highly expressed in 
pancreatic islets. 
T2D (ClinVar=RCV000001055.1). 
Reduced islet zinc content. abnormal beta-cell 
morphology on EM. Inconsistent effects on insulin 
processing and glucose-induced insulin secretion in 
vitro. Increased hepatic insulin clearance. 
Intraperitoneal glucose tolerance tests show impaired 
glucose tolerance in young mice (4-6 weeks) (PMID 
24051378, PMID 24751356). 
THADA 
"Thyroid adenoma-associated protein". Locus is disrupted by chromosomal 
rearragnements involving 2p21 in some benign thyroid adenomas (PMID 
12955091). Associated with lower beta-cell response to GLP-1 and arginine 
(PMID 19833888). Ubiquitously expressed transcript. 
T2D (OMIM 125853). Crohn's disease (PMID 21102463). 
Prostate cancer (PMID 19767753). Multiple Sclerosis (PMID 
22190364). Polycystic ovary syndrome (PMID 21151128). 
No knockout reported. 
TM6SF2 
"Transmembrane 6 superfamily member 2". Gene located in the CILP2-TMS6F2 
locus identified by T2D GWA Studies. Ubiquitously expressed transcript encodes 
endoplasmic reticulum protein that regulates fat metabolism in liver (PMID 
24927523). 
T2D (PMID 22885922). Glu167Lys variant associated with 
increased susceptibility to nonalcoholic fatty liver disease 
(PMID 24531328), increased total cholesterol and 
myocardial infarction risk (PMID 24633158). 
No knockout reported. Adeno-associated virus-
mediated shRNA knockdown increased hepatic 
triglyceride content and decreased very-low-density 
lipoprotein secretion (PMID 24531328). 
TSPAN8 "Tetraspanin-8". Member of the transmembrane 4 glycoprotein superfamily, which is known to interact with integrins. 
SNPs (PMID 18372903) and CNV (PMID 20360734) near 
TSPAN8 associated with T2D. 
Lower total body weight, lower fat and lean mass 
(males only). Lower bone mineral density and 
phosphorus levels (males only) (PMID 20733586). 
WFS1 
"Wolframin". Endoplasmic reticulum protein involved in cellular Ca++ homeostasis. 
Functions in pancreatic beta cell and neuronal survival. Mutations can cause 
Wolfram Syndrome (also known as DIDMOAD - Diabetes Insipidus. Diabetes 
Mellitus. Optic Atrophy and Deafness). 
T2D (PMID 17603484). Wolfram syndrome 1 (OMIM 
222300). Autosomal dominant deafness 6 (OMIM 600965) 
Reduced beta cell mass. Activated ER-stress 
response associated with apoptosis in beta-cells. 
Increased blood glucose and decreased insulin 
secretion (PMID 15056606, PMID 16215705, PMID 
19041897). 
Supplementary Table 11a | Gene-level mask descriptions. Protein truncating (PTV) and missense variants 
were further annotated to identify variants predicted deleterious by at least one (NSbroad) or each of five (NSstrict) 
prediction algorithms (LRT, Mutation Taster, PolyPhen2-HumDiv, PolyPhen2-HumVar, SIFT). PTV, missense, 
NSstrict, and NSbroad classes of variants were combined to generate four masks for gene-level testing (described 
in first column).  The second column lists variant categories (and variant counts) contributing to each mask; the 
third column indicates the total numbers of variants in each mask; the fourth column indicates the number of 
genes containing at least one variant meeting mask criteria; the final column indicates the median number (and 
range) of variants per gene for each mask. 
Mask name and description Variant classes (number of variants) 
Number of 
variants 
Number of 
genes 
Median number of 
variants/gene [range] 
1) Mask 1 - PTV-only 
Predicted protein-truncating variants (PTVs) 
PTVs (69,956) 69,956 14,415 3 [1-135] 
2) Mask 2 - PTV + missense 
PTVs and missense variants with MAF<1%, as 
high-frequency variants may be less likely to be 
deleterious  
PTVs (69,956) 
missense, MAF<1% 
(1,065,607) 
1,135,563 17,806 47 [1-4284] 
3) Mask 3 - PTV + NSstrict 
PTVs and missense variants predicted 
deleterious by all five algorithms (NSstrict): LRT, 
Mutation Taster, PolyPhen2-HumDiv, 
PolyPhen2-HumVar, SIFT 
PTVs (69,956) 
NSstrict (131,976) 
201,932 16,757 8 [1-429] 
4) Mask 4 - PTV + NSbroad 
PTVs and NSstrict variants, plus missense 
variants predicted deleterious by at least one 
algorithm (NSbroad) and with MAF<1% 
PTVs (69,956) 
NSstrict (131,976) 
NSbroad, MAF<1% 
(603,369) 
805,301 17,771 33 [1-2124] 
Supplementary Table 11b | Numbers of variants for each mask in 12,940 WES samples. 
 
Supplementary Figure 12 | Manhattan plots for gene-level analysis in 12,940 WES samples 
FES 
2.5x10-6 
2.5x10-5 
a. Mask 1 - PTV-only  
b. Mask 2 - PTV + missense  
c. Mask 3 - PTV + NSstrict 
d. Mask 4 - PTV + NSbroad 
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Supplementary Table 14B | FES gene-level association statistics for all ancestry 
groups (African American N=2,074; East Asian N=2,165; European N=4,541; 
Hispanic N=1,943; South Asian N=2,217; Total N=12,940) for Mask 4 (PTV + 
NSbroad).  
Samples 	  
No. variants; 
MAC control / 
case 	  
Max. single-marker 
MAC (%) 	   SKAT-O	  p-value	   Top single-marker p-value 	  
Afr. Amer.	   23; 25/25	   12 (24)	   0.83	   0.13	  
E. Asian	   18; 15.2/10	   3 (11.9)	   0.68	   0.11	  
European	   24; 21/17	   6 (15.8)	   0.51	   0.062	  
Hispanic	   12; 5/10.5	   3 (19.4)	   0.22	   0.068	  
S. Asian	   21; 19/45	   38 (59.4)	   7.2x10-6	   7.5x10-6	  
All	   81; 85.3/107.6	   38 (19.7)	   1.9x10-5	   7.5x10-6	  
Supplementary Figure 14A |  Single variant analyses in GWAS regions. The QQ 
plots display single variant analyses for all variants (left) and nonsynonymous variants 
only (right). Analyses of exome sequence (6,504 cases; 6,436 controls) are in the 
upper panels, and of the combination of exome sequence and exome array data 
(34,809 cases, 57,985 controls) in the lower. In each panel, variants mapping to 
established GWAS regions are in pink, and all other variants in blue (only variants with 
a minor allele count over 9 are included). The plots show enrichment of association 
signals for coding variants in established GWAS signals resulting from a combination 
of linkage disequilibrium to known common variant GWAS signals, and secondary 
signals at a subset of loci (eg HNF4A, THADA, TSPAN8).  
Ancestry Study Citation(s) PubMed ID(s) T2D Case Ascertainment T2D Control Ascertainment T1D and MODY exclusion criteria Genotyping array Calling algorithm Association covariates
European Oxford-based UK T2D case-control Voight BF et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. 
Nat Genet. 2010 Jul;42(7):579-89. 
Spector TD, Williams FM.The UK Adult Twin Registry (TwinsUK). Twin Reserch and Human Genetics 2006; 
9 (6): 899-906.
Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F. The in vivo 
effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of 
the Oxford Biobank. Diabetologia. 2006 Jan;49(1):158-68.
Strachan DP, et al. Lifecourse influences on health among British adults: Effects of region of residence in 
childhood and adulthood. Int. J. Epidemiol. 2007;36:522-531.
20581827, 
17254428, 
16362285, 
17255346
The T2D cases were selected from UK Caucasian subjects who are part of the Diabetes UK 
Warren 2 repository. The 
remainder were recruited as isolated cases but these cases were (compared to population-based 
cases) of relatively early onset and had a high proportion of T2D parents and/or siblings. T2D 
was defined as current prescribed treatment with sulphonylureas, biguanides, other oral agents 
and/or insulin or, in the case of individuals treated with diet alone, historical or contemporary 
laboratory evidence of hyperglycemia.
Controls from all sources were selected without reference to T2D status and 
fasting glucose ≤7.0 mmol/l.
Individuals with maturity-onset diabetes of the young and 
mitochondrial diabetes, were excluded. Other inclusion criteria 
included: absence of first-degree relatives with type 1 diabetes; an 
interval of ≥1 year between diagnosis and institution of regular insulin 
therapy; and negative testing for antibodies to glutamic acid 
decarboxylase (anti-GAD). An anti-GAD titer >10 U (corresponding to 
~8 SD above the mean of 88 normal control subjects) in duplicate 
samples was considered positive.
Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
zCall
European The Diabetes Audit and Research in 
Tayside Scotland (GoDarts)
Morris AP et al. Large-scale association analysis provides insights into the genetic architecture and 
pathophysiology of type 2 diabetes. Nat Genet. 2012 Sep;44(9):981-90. 
22885922 Cases had T2D diagnosed between the ages of 35-70 years (inclusive). The diagnosis of 
diabetes was based on either current prescribed treatment with diabetes-specific medication or, 
in the case of individuals treated with diet alone, laboratory evidence of diabetes as defined by 
the WHOS8,S38. 
Controls were defined as having no diagnosis of diabetes at the time of 
recruitment (or subsequently), fasting glucose ≤7.0 mmol/l, HbA1c ≤6.4% and 
age < 80 years. 
Cases were excluded if they had an established (clinical and/or 
molecular) diagnosis of monogenic diabetes (e.g. maturity-onset 
diabetes of the young, mitochondrial diabetes) or if they had been 
treated with regular insulin therapy within 1 year of diagnosis. No islet 
autoantibodies were measured. 
Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
zCall
European Prospective Investigation of the 
Vasculature in Uppsala Seniors 
(PIVUS)
Lind L et al. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the 
elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler 
Thromb Vasc Biol 2005 25 2368-2375
16141402 Known T2D or fasting whole blood glucose ≥ 6.1mmol/l Controls were defined as having no diagnosis of diabetes at the time of 
recruitment (or subsequently), whole blood glucose ≤6.0 mmol/l.
- Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
zCall
European Uppsala Longitudinal Study of Adult 
Men (ULSAM)
Ingelsson, E. et al. Insulin resistance and risk of congestive heart failure. Jama 294, 334-41 (2005). 16030278 Hospital discharge register-defined diabetes before 2002 Controls were defined as having no diagnosis of diabetes at the time of 
recruitment.
- Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
zCall
European Metabolic Syndrome in Men Study 
(METSIM)
Stancakova, A. et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose 
tolerance in 6,414 Finnish men. Diabetes 58, 1212–1221 (2009)
19223598 T2D as classified by WHO 1997 criteria (fasting plasma glucose >= 7.0 mmol/l or 2-hr plasma 
glucose >= 11.1 mmol/l)
NGT as classified by WHO 1997 criteria  (fasting plasma glucose < 6.1 
mmol/l and 2-hr plasma glucose < 7.8 mmol/l) 
known T1D cases excluded Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
manual review
age, batch
European FIN-D2D 2007 Kotronen A, Yki-Järvinen H, Männistö S, Saarikoski L, Korpi-Hyövälti E, Oksa H, Saltevo J, Saaristo T, 
Sundvall J, Tuomilehto J, Peltonen M. Non-alcoholic and alcoholic Fatty Liver Disease – two Diseases of 
Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey. BMC Public 
Health 2010; 10: 237.
20459722 T2D as classified by WHO 1999 criteria (fasting plasma glucose >= 7.0 mmol/l or 2-hr plasma 
glucose >= 11.1 mmol/l)
NGT as classified by WHO 1999 criteria (fasting plasma glucose < 6.1 mmol/l 
and 2-hr plasma glucose < 7.8 mmol/l) 
known T1D cases excluded Illumina HumanExome-12v1-1_A 
Beadchip 
Illumina GenCall using standard 
Illumina cluster files + Zcall
age, sex
European The Dose Responses to Exercise 
Training (DR's EXTRA) Study
Diet, fitness and metabolic syndrome - The DR's EXTRA Study.  Kouki R, Schwab U, Lakka TA, Hassinen M, 
Savonen K, Komulainen P, Krachler B, Rauramaa R. Nutr Metab Cardiovasc Dis. 2012 Jul;22(7):553-60. 
Epub 2010 Dec 24
21186108 T2D as classified by WHO 1999 criteria (fasting plasma glucose >= 7.0 mmol/l or 2-hr plasma 
glucose >= 11.1 mmol/l) or physician diagnosed
NGT as classified by WHO 1999 criteria (fasting plasma glucose < 6.1 mmol/l 
and 2-hr plasma glucose < 7.8 mmol/l) 
known T1D cases excluded Illumina HumanExome-12v1-1_A 
Beadchip 
Illumina GenCall using standard 
Illumina cluster files + Zcall
age, sex
European National FINRISK 2007 Study 
(FINRISK 2007)
Thirty-five-year trends in cardiovascular risk factors in Finland. Vartiainen E, Laatikainen T, Peltonen M, 
Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Int J Epidemiol. 2010 
Apr;39(2):504-18
19959603 T2D as classified by WHO 1999 criteria (fasting plasma glucose >= 7.0 mmol/l or 2-hr plasma 
glucose >= 11.1 mmol/l)
NGT as classified by WHO 1999 criteria; frequency matched to cases by birth 
province; BMI ≥18.5 kg/m2; within each birth province, prioritized samples 
with highest values for age + 2*BMI
known T1D cases excluded Illumina HumanExome-12v1-1_A 
Beadchip 
Illumina GenCall using standard 
Illumina cluster files + Zcall
age, sex
European Finland-United States Investigation 
of NIDDM Genetics (FUSION) Study
Valle, T. et al. Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM 
Genetics (FUSION) Study. Diabetes Care 21(6), 949-958 (1998); Scott, L. et al. A genome-wide association 
study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316(5829), 1341-1345 
(2007)
9614613; 
17463248
T2D as classified by WHO 1999 criteria, by report of diabetes medication use, or based on 
medical record review
NGT as classified by WHO 1999 criteria; approximately frequency matched to 
the cases by 5-year age category, sex, and birth province.
known T1D cases excluded Illumina HumanExome-12v1-1_A 
Beadchip 
Illumina GenCall using standard 
Illumina cluster files + Zcall
age, sex
European Prevalence, Prediction and 
Prevention of diabetes (PPP) 
(Finnish)
Isomaa B, Forsén B, Lahti K, Holmström N, Wadén J, Matintupa O, Almgren P, Eriksson JG, Lyssenko V, 
Taskinen MR, Tuomi T, Groop LC. A family history of diabetes is associated with reduced physical fitness in 
the Prevalence, Prediction and Prevention of Diabetes (PPP)-Botnia study. Diabetologia. 2010 
Aug;53(8):1709-13. 
20454776 Diagnosis of diabetes was based on an OGTT or a history of previously known diabetes applying 
WHO criteria. In uncertain cases, the diagnosis was confirmed from patient records. 
No previously known diabetes. Free from diabetes after an OGTT applying 
WHO criteria.
Illumina HumanExome-12v1_A 
Beadchip 
Custom birdseed algorithm 
within batch
age, sex, analysis 
performed within batch
European Diabetes Registry Vaasa (DIREVA) 
(Finnish)
- Previous diagnosis of T2D
- Normal C-peptide levels                                                                              
- No Anti-GAD antibody                                                                                  
No controls are in the registry No Anti-GAD antibody and normal C-peptide levels Illumina HumanExome-12v1_A 
Beadchip 
Custom birdseed algorithm 
within batch
age, sex, analysis 
performed within batch
European All New Diabetics In Scania (ANDiS)  
(Swedish)
- Previous diagnosis of T2D
- Normal C-peptide levels                                                                              
- No Anti-GAD antibody                                                                                  
No controls are in the registry No Anti-GAD antibody and normal C-peptide levels Illumina HumanExome-12v1_A 
Beadchip 
Custom birdseed algorithm 
within batch
age, sex
European Malmö Diet and Cancer (MDC) 
(Swedish)
Manjer J, Carlsson S, Elmståhl S, Gullberg B, Janzon L, Lindström M, Mattisson I, Berglund G. The Malmö 
Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. 
Eur J Cancer Prev 2001;10:489-99. and Manjer J, Elmståhl S, Janzon L, Berglund G. Invitation to a 
population-based cohort study: differences between subjects recruited using various strategies. Scand J 
Public Health 2002;30:103-12.
11916347     
12028859 
DM at baseline was defined as self-report of a physician diagnosis or use of diabetes medication 
or fasting whole blood glucose greater than or equal to 6.1  mmol/l (corresponding to fasting 
plasma glucose concentration >= 7.0  mmol/l).
Fasting blood glucose below 6.1  mmol/l (corresponding to fasting plasma 
glucose concentration >= 7.0  mmol/l).
None Illumina 
HumanOmniExpressExome-
8v1_B
Custom birdseed algorithm 
within batch
age, sex, analysis 
performed within batch
European Scania Diabetes Registry (SDR) 
(Swedish)
Lindholm E, Agardh E, Tuomi T, Groop L, Agardh C.D. Classifying diabetes according to the new WHO 
clinical stages. Eur J Epidemiol 2001;17, 983-9.
12380709 Physicians own classification into T2D, based on WHO 1985 guidelines (before 2001) or WHO 
1999 guidelines (diagnosed after January 2001).
No controls are in the registry Presenve of severe hyperglycaemia and/or ketosis at diagnosis, low 
fasting C-peptide levels and presence or GAD antibodies
Illumina HumanExome-12v1_A 
Beadchip 
Custom birdseed algorithm 
within batch
age, sex, analysis 
performed within batch
European Nurses' Health Study (NHS) Qi L et al. Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Human Molecular 
Genetics 2010;19(13):2706-15
20418489  Diabetes cases were defined as self-reported diabetes confirmed by a validated supplementary 
questionnaire. For cases before 1998, diagnosis was made using criteria consistent with those 
proposed by the National Diabetes Data Group. We used the American Diabetes Association 
diagnostic criteria for diagnosis of diabetes cases during the 1998 and 2000 cycles. A 98% of self-
reported cases were confirmed by medical records review.
Controls were defined as those free of diabetes at the time of diagnosis of the 
case and remained unaffected through follow-up
NA Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
manual review
age
European Health Professional Follow-Up Study 
(HPFS)
Qi L et al. Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Human Molecular 
Genetics 2010;19(13):2706-15
20418489  Diabetes cases were defined as self-reported diabetes confirmed by a validated supplementary 
questionnaire. For cases before 1998, diagnosis was made using criteria consistent with those 
proposed by the National Diabetes Data Group. We used the American Diabetes Association 
diagnostic criteria for diagnosis of diabetes cases during the 1998 and 2000 cycles. A 98% of self-
reported cases were confirmed by medical records review.
Controls were defined as those free of diabetes at the time of diagnosis of the 
case and remained unaffected through follow-up
NA Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
manual review
age
European Estonian Genome Center, University 
of Tartu (EGCUT)
Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, Perola M, Ng PC, Mägi R, Milani L, 
Fischer K, Metspalu A. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. 
Int J Epidemiol. 2014 Feb 11.
24518929 - Previous diagnosis of T2D Population based controls with fasting glucose < 7 mmol/l NA Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenCall + zCALL age, sex 
European EFSOCH and DARE The Exeter Family Study of Childhood Health (EFSOCH): study protocol and methodology. Knight B, Shields 
BM, Hattersley AT.
16466435 Type 2 diabetic individuals were ascertained from the Exeter branch of the Diabetes Alliance for 
Research in England (DARE) study and selected for genotyping if they were not on insulin within 
the first year of diagnosis and diagnosed after the age of 35 years. 
Control individuals were selected from the Exeter Family Study of Childhood 
health (EFSOCH). Male and female partners were ascertained at the time of 
pregnancy and included on the basis that they represent a very similar 
geographic distribution to the DARE case individuals, and were 
normoglycaemic on the basis of fasting glucose of HbA1C.
age at diagnosis 35 years of over. Not on insulin for first year of 
diagnosis.
Illumina HumanExome-12v1_A 
Beadchip 
Illumina + zCall age and sex
European Cooperative Health Research in the 
Region of Augsburg [KORA]
Holle R, Happich M, Löwel H, Wichmann HE, MONICA/KORA Study Group. KORA - a research platform for 
population based health research. Gesundheitswesen. 2005 Aug;67 Suppl 1:S19-25.                                                                  
Wichmann, H.E., Gieger, C. & Illig, T. KORA-gen-resource for population genetics, controls and a broad 
spectrum of disease phenotypes. Gesundheitswesen 67, Suppl. 1, S26-S30 (2005).
16032513, 
16032514
- Previous diagnosis of T2D, or both fasting and 2-hr criteria met for new T2D diagnosis                                                                               
- Family history of diabetes (parents, sibs, children, grandparents, avuncular, cousins)
- Unrelated individuals based IBS analyses
- No diagnosis of T2D
- Normal glucose tolerance at baseline
- Unrelated samples
- Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain + zCall age, sex
European Danish T2D case-control Albrechtsen, A. et al. Exome sequencing-driven discovery of coding polymorphisms associated with common 
metabolic phenotypes. Diabetologia 56, 298-310 (2013)
23160641 Screen-detected (by fasting glucose or 2-hr glucose after OGTT) or clinical onset type 2 diabetes 
(WHO 1999 criteria)
Population-based sampled with fasting glucose < 6.1 mmol/L and 2-hr 
glucose < 7.8 (if measured) (WHO 1999 criteria)
Fasting C-peptide <150 pmol/L Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenTrain version 1.0  + 
zCall
age, sex, (BMI)
European GLACIER Hallmans, G., et al., Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study 
Cohort - evaluation of risk factors and their interactions. Scand J Public Health Suppl, 2003. 61: p. 18-24.
14660243  - Participants with incident type 2 diabetes were identified from the Diabetes Register in Northern 
Sweden (DiabNorth) Web: http://www.diabetesregister.se/en/about-diabnorth-and-the-diabetes-
register
 - fasting glucose <5.6 mmol/l  - Illumina HumanExome Beadchip 
12 v1.1
Illumina GenTrain + zCall age, sex, 1-10 principal 
components, (BMI)
European EPIC-Norfolk (T2D cases) and the 
Fenland study (cohort)
Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective 
Investigation of Cancer. British journal of cancer 80 (supp 1), 95-103 (1999); Rolfe, E. et al. Association 
between birth weight and visceral fat in adults. AJCN 92(2), 347-52 (2010)
10466767; 
20519560
Clinically diagnosed incident cases of T2D from the EPIC-Norfolk study and prevalent 
undiagnosed T2D in the Fenland study based on fasting glucose >=7.0 mmol/L and/or 2hGlu 
>=11.1mmol/L. 
Random sample of population-based Fenland study with FG<7.0mmol/L and 
2h-glucose <11.1mmol/L. 
NA Illumina HumanExome-12v1_A 
Beadchip 
Illumina GenCall + zCall age, sex, (BMI)
Supplementary Table 15a | Exome array cohort information
Cases Controls
Ancestry Study N Total N Case # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2 Mean age of diagnosis (SD), years N Control # Females (%) Mean age (SD), years Mean BMI (SD), kg/m2
European Oxford-based UK T2D case-control 12743 1861 767 (51.7) F: 53.3 (11.4) F: 34.1 (7.2) F: NA 10882 5623 (41.2) F: 48.5 (9.0) F: 25.9 (5.0)
M: 53.1 (10.3) M: 31.2 (5.6) M: NA M: 50.7 (7.7) M: 27.2 (4.0)
European The Diabetes Audit and Research in Tayside Scotland (GoDarts) 3508 1715 682 (39.8) F: 64.2 (9.4) F: 33.3 (6.9) F: NA 1793 820 (45.7) F: 57.9 (11.4) F: 26.6 (4.8)
M: 63.2 (9.4) M: 31.5 (5.8) M: NA M: 59.5 (11.0) M: 27.3 (4.0)
European Prospective Investigation of the Vasculature in Uppsala Seniors 
(PIVUS)
961 111 46 (41.1) F: 70.2 (0.1) F: 29.9 (6.7) F: NA 850 428 (50.3) F: 70.3 (0.15) F: 26.8 (4.6)
M: 70.1 (0.1) M: 26.6 (3.8) M: NA M: 70.1 (0.17) M: 28.6 (3.8)
European Uppsala Longitudinal Study of Adult Men (ULSAM) 1101 160 0 (0) F: NA F: NA F: NA 941 0 (0) F: NA F: NA
M: 71.0 (0.7) M: 28.0 (4.0) M: NA M: 71.0 (0.63) M: 25.9 (3.2)
European Metabolic Syndrome in Men Study 5158 773 0 (0) F: 0 (0) F: 0 (0) F: NA 4385 0 (0) F: 0 (0) F: 0 (0)
M: 60.7 ( 6.7) M: 29.9 (5.2) M: NA M: 57.1 (7.2) M: 26.2 (3.5)
European FIN-D2D 2007 2026 646 274 (42.4) F: 64.0 (7.1) F: 31.5 (6.0) F:61.2 (10.4) 1380 827 (59.9) F: 58.3 (8.1) F:26.1 (4.8)
M: 63.9 (7.5) M: 29.8 (4.9) M: 60.4 (9.0) M: 58.7 (8.3) M: 26.2 ( 3.6)
European The Dose Responses to Exercise Training (DR's EXTRA) Study 558 81 45 (55.5) F: 66.8 (5.7) F: 31.9 (5.4) F: NA 477 360 (75.4) F: 65.5 (5.1) F: 26.7 (4.5)
M: 68.2 (6.2) M: 30.1 (4.6) M: NA M: 66.9 (6.3) M: 26.3 (3.2)
European National FINRISK 2007 Study (FINRISK 2007) 2606 1112 443 (39.8) F: 61.4 (8.3) F: 31.9 (6.1) F: 58.3 (10.2) 1494 682 (45.6) F: 62.5 (7.0) F: 28.3 (4.8)
M: 59.4 ( 9.4) M: 30.3 (4.3) M: 56.8 (10.0) M: 60.0 (7.9) M: 27.3 (3.4)
European Finland-United States Investigation of NIDDM Genetics (FUSION) 
Study
1467 981 439 (44.7) F: 63.8 (7.9) F: 31.0 (5.3) F: 54.9 (8.7) 486 270 (55.5) F: 62.6 (8.2) F: 26.4 (4.0)
M: 62.0 (7.3) M: 29.3 (4.4) M: 53.6 ( 8.0) M: 62.3 (9.4) M: 26.1 (3.5)
European Prevalence, Prediction and Prevention of diabetes (PPP) (Finnish) 4969 311 127 (41) F: 64.0 (10.8) F: 30.1 (5.5) F: 55.8 (15.4) 4658 2505 (54) F: 48.8 (15.6) F: 25.9 (4.7)
M: 61.4 (12.5) M: 30.1 (5.0) M: 52.6 (12.9) M: 48.6 (15.5) M: 26.7 (3.8)
European DIREVA (Diabetes Registry Vaasa) (Finnish) 2601 2601 1147 (44) F: 67.3 (10.8) F: 31.3 (5.6) F: 59.9 (10.6) 0 F: NA F: NA F: NA
M: 65.8 (10.1) M: 30.2 (5.2) M: 58.6 (10.3) M: NA M: NA M: NA
European Malmö Diet and Cancer (MDC) (Swedish) 5613 440 192 (43) F: 60.3 (5.3) F: 30.4 (5.0) F: NA 5173 3080 (55) F: 57.3 (5.9) F: 26.3 (4.1)
M: 58.7 (5.8) M: 29.4 (4.6) M: NA M: 57.3 (6.0) M: 26.9 (3.5)
European All New Diabetics In Scania (ANDiS)  (Swedish) 1928 1928 776 (40) F: 62.9 (11.6) F: 32.9 (5.7) F: 62.7 (11.5) 0 F: NA F: NA F: NA
M: 61.6 (11.3) M: 31.6 (4.9) M: 61.4 (11.2) M: NA M: NA M: NA
European Scania Diabetes Registry (SDR) (Swedish) 3192 3192 1312 (41) F: 62.6 (13.2) F: 30.5 (6.2) F: 56.9 (14.0) 0 F: NA F: NA F: NA
European Nurses' Health Study (NHS) 3088 1334 100 (100) F: 43.4 (6.7) F: 27.3 (4.9) F: NA 1754 100 (100) F: 43.2 (6.7) F: 23.9 (3.0)
M: NA M: NA M: NA M: NA M: NA
European Health Professional Follow-Up Study (HPFS) 2411 1113 0 (0) F: NA F: NA F: NA 1298 0 (0) F: NA F: NA
M: 55.5 (8.5) M: 27.8 (4.0) M: NA M: 55.5 (8.4) M: 25.0 (2.7)
European Estonian Genome Centre, University of Tartu (EGCUT) 2388 882 385 (43.7) F: 62.0 (11.2) F: 31.6 (5.0) NA 1506 666 (44.2) F: 47.2 (16.8) F: 27.0 (4.1)
M:64.7 (10.8) M:32.6 (5.6) NA M: 46.8 (17.2) M: 26.4 (5.3)
European EFSOCH and DARE 3013 1446 564 (39.1) F: 66.2 (9.02) F: 32.1 (6.2) F:N/A 1567 815 (52.3) F:  30.4 (5.3) F: 28.01 (4.6)
M:65.9 (8.9) M: 30.6 (5.2) M: N/A M: 32.9 (5.9) M: 26.6 (3.9)
European Cooperative Health Research in the Region of Augsburg [KORA] 3738 959 434 (45.3) F: 62.7 (8.6) F: 32.1 (5.7) F: NA 2779 1436 (51.7) F: 48.0 (13.1) F: 26.5 (5.0)
M: 61.2 (8.7) M: 30.1 (4.7) M: NA M: 48.8 (13.2) M: 27.3 (3.7)
European Danish T2D case-control 10860 5864 2343 (40.0) F: 61.2 (9.6) F: 31.2 (6.2) F: 54.9 (10.7) 4996 2716 (54.4) F: 45.3 (7.9) F: 25.0 (4.4)
M: 61.4 (8.8) M: 30.2 (4.9) M: 54.2 (10.0) M: 45.3 (7.9) M: 26.1 (3.6)
European GLACIER 1925 960 457 (47.60%) F: 55.2 (6.7) F: 30.6 (5.4) NA 965 526 (54.51%) F: 50.5 (7.7) F: 25.4 (5.5)
M: 54.3 (7.5) M: 29.5 (4.2) NA M: 49.6 (8.5) M: 26.1 (4.4)
European EPIC-Norfolk (T2D cases) and the Fenland study (cohort) 1848 691 324 (47%) F: 52.7 (9.9) F: 27.6 (5.7) F: 68.5 (8.4) 1157 631 (54.5%) F: 48.5 (7.3) F: 26.5 (5.6)
M: 53.9 (10.1) M: 28.1 (4.0) M: 68.3 (8.3) M: 48.2 (7.3) M: 27.3 (4.0)
Supplementary Table 15b | Exome array sample characteristics
Supplementary Figure 16 | Overlap of variants detected in 12,940 trans-ethnic exomes and 
genotyped on exome array in 79,854 Europeans. Each blue bar indicates the number of coding 
SNVs, protein-altering SNVs (nonsense, essential splice site, and missense variants), or MAF > 0.5% 
protein-altering variants observed in 12,940 sequenced samples, broken down by ancestry (African 
American N=2,074; East Asian N=2,165; European N=4,541; Hispanic N=1,943; South Asian 
N=2,217). Red bars indicate the numbers of sequence variants that were observed in 79,854 
European exome array samples. Exact counts are shown in the table on the right. While a small 
fraction of all coding variants are represented on exome array, 81.6% of European protein-altering 
variants with MAF >0.5% are captured using the array. 
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   9.9	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Supplementary Figure 17 | Unconditional regional association plots for coding variants from 
GoT2D consortium data (N=2,657). Each plot shows the p-value (on a -log10 scale) as a function of 
genomic position (NCBI Build 37) covering a 2-Mb window around the novel exome-wide significant 
coding variant (indicated by the purple symbol). The color-coding of all other SNPs indicates LD with 
the novel coding SNP estimated from GoT2D data: red, r2 ≥ 0.8; gold, 0.6 ≤ r2 < 0.8; green, 0.4 ≤ r2 < 
0.6; cyan, 0.2 ≤ r2 < 0.4; blue, r2 < 0.2; gray, r2 unknown. Recombination rates are estimated from 
Phase II HapMap, and gene annotations are taken from the UCSC genome browser. Imputation 
quality was modest for rs60980157 (GSPM1) and rs9379084 (RREB1) (both r2=0.84) and high for all 
other novel coding SNPs (r2>0.99). 
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Supplementary Table 18 | Association summary statistics for coding variants in GWAS regions from previous European ancestry meta-analysis from the DIAGRAM consortium. 
Locus rsID Change Combined exomes Exome-array 
GWAS 
(Morris et al. 2012) 
GWAS + Metabochip 
(Morris et al. 2012) Comments 
p-value N p-value N p-value N p-value N  
PAM/PPIP5K2 
rs35658696 Asp563Gly 5.7x10
-
10 67,171 1.7x10
-7 66,047 NA NA NA NA Lead coding SNP from exome-array meta-analysis 
rs36046591 Ser1207Gly 3.3x10-8 65,569 1.0x10-6 62,201 NA NA NA NA  
rs7729395 non-coding NA NA NA NA 0.008 63,390 1.0 x 10-5 80,645 
Best proxy for the lead coding variant in Morris et al. (2012) 
(r2=0.79) 
MTMR3/ASCC2 
rs41278853 Asn960Ser 5.6x10-9 82,784 3.2x10-6 79,852 NA NA NA NA Lead coding SNP from exome-array meta-analysis 
rs11549795 Val123Ile 1.0x10-7 82,784 2.0x10-5 79,854 0.0025 32,933 NA NA  
rs28265 Asp407His 1.1x10-7 82,784 1.9x10-5 79,849 0.0004 63,390 NA NA  
rs36571 Pro423Ser 3.0x10-7 82,784 2.0x10-5 79,854 0.00041 63,390 NA NA  
rs16988333 non-coding NA NA NA NA 0.00012 65,812 3.7x10-6 82,788 Best proxy for the lead coding variant in Morris et al. (2012) (r2=1) 
rs5997539 non-coding NA NA NA NA 7.7x10-5 69,033 7.7x10-6 80,480 Lead SNP from Morris et al. (2012) (r
2=0.74 with lead coding 
variant) 
WFS1 
rs1801214 Asn500Asn 1.5x10
-
14 82,784 2.0x10
-12 79,854 1.3x10-8 63,390 3.3x10
-
15 80,640 Lead coding SNP from exome-array meta-analysis 
rs1801212 Val333Ile 9.0x10
-
14 82,784 9.3x10
-12 79,852 9.3x10-5 69,033 3.6x10
-
11 83,539  
rs734312 Arg611His 6.9x10
-
11 82,783 1.3x10
-10 79,852 3.2x10-7 63,390 5.5x10
-
11 77,231  
rs4689388 non-coding NA NA 2.3x10-11 79,854 3.3x10-7 63,390 2.1x10
-
12 77,732  
rs4458523 non-coding NA NA NA NA 2.0x10-7 69,033 2.0x10
-
15 85,051 
Lead Morris et al. (2012) variant (r2=1 with lead coding SNP 
from exome-array analysis) 
CILP2/TM6SF2 rs58542926 Glu167Lys 
3.2x10-
10 82,784 1.9x10
-7 79,854 NA NA 4.2x10-7 54,462 Lead coding SNP from exome-array meta-analysis 
rs10401969 non-coding NA NA 4.2x10-7 79,854 0.00054 69,033 7.0x10-9 86,196  
RREB1 
rs9379084 Asp1171Asn 4.0x10-9 56,339 1.1x10-5 52,998 NA NA 0.00022 54,618 Lead coding SNP from exome-array meta-analysis 
rs9502570 non-coding NA NA NA NA 0.00061 63,390 NA NA Lead SNP from Mahajan at el. (2014) (r
2=0.01 with the lead 
coding variant from exome-array analysis) 
HNF4A 
rs1800961 Thr139Ile 2.9.x10-6 82,784 9.5x10-7 79,854 0.025 60,203 0.00027 76,816 Lead coding SNP from exome-array meta-analysis 
rs4812831 non-coding NA NA 4.7x10-5 79,854 0.016 69,033 NA NA Top SNP in Kooner et al. (2010) (r
2=0.01 with the lead coding 
variant from exome-array analysis) 
THADA 
rs35720761 Cys1650Tyr 3.3x10
-
10 82,784 3.5x10
-8 79,845 NA NA NA NA Lead coding SNP from exome-array meta-analysis 
rs7578597 Thr1187Ala 1.3x10-5 47,251 5.1x10-5 37,704 1.6x10-5 63,390 2.0x10-9 78,010  
rs10203174 non-coding NA NA NA NA 1.5x10-6 69,033 9.5x10
-
12 86,197 
Lead Morris et al. (2012) variant (r2=0.48 with lead coding SNP 
from exome-array analysis) 
COBLL1 
rs7607980 Asn939Asp 8.3x10
-
15 82,784 4.7x10
-11 79,853 0.0067 69,033 2.9x10-7 86,195 Lead coding SNP from exome-array meta-analysis 
rs13389219 non-coding NA NA 1.9x10-10 79,850 0.0096 63,390 1.0x10-8 80,649 Lead Morris et al. (2012) variant (r
2=0.77 with lead coding SNP 
from exome-array analysis) 
TSPAN8 
rs1051334 Ser213Ala 2.7x10-6 62,197 3.5x10-5 58,536 0.00018 63,390 0.00043 80,646 Lead coding SNP from exome-array meta-analysis 
rs4760790 non-coding NA NA 8.6x10-6 79,854 8.0x10-6 63,390 NA NA Lead SNP from Morris et al. (2012) (r
2=0.24 with lead coding 
variant) 
 
Combined exomes p-values are derived from the meta-analysis of sequence and array datasets, with total sample size up to 92,794 (34,809 cases, 57,985 controls: effective sample size 82,758); smaller sample 
 sizes reflect the fact that many variants were monomorphic in some or all of the non-European sequence cohorts. Exome-array analysis was performed in up to 79,854 samples (28,305 cases, 51,549 controls: 
 effective sample size 69,866). Previously reported p-values from European meta-analysis are taken from Morris et al. (2012) Large-scale association analysis provides insights into the genetic architecture and  
pathophysiology of type 2 diabetes. Nat Genet. 44(9):981-90. 
 
Supplementary Table 19 | Association summary statistics for T2D and fasting glucose levels from exome-array and exome sequence for selected RREB1 coding variants. 
  T2D association Fasting glucose (adjusted for BMI) association 
Asp1171Asn (rs9379084) 
  Neff EAF (%) p-value OR (95% CI) I2 Cochran’s Q p_het N EAF (%) p-value 𝜷 (SE) I2 Cochran’s Q p_het 
Within-
ancestry 
African Americans 2,074 97.6 0.00033 2.26 (1.81-2.71) - - - 508 96.9 0.82 -0.040 (0.190) - - - 
East Asians 2,165 86.6 0.062 1.20 (1.01-1.38) - - - 1,104 85.7 0.22 0.075 (0.062) - - - 
Europeans 4,541 89.5 0.0025 1.23 (1.09-1.37) - - - 2,144 88.7 0.78 -0.014 (0.049) - - - 
Hispanics 1,943 92.5 0.21 1.16 (0.92-1.41) - - - 844 93.0 0.7 -0.037 (0.094) - - - 
South Asians 2,217 89.9 0.071 0.86 (0.61-1.11) - - - 508 87.2 0.39 0.085 (0.098) - - - 
Meta-
analysis 
Exome sequence 12,918 86.6-97.6 2.2x10-5 1.19 (1.10-1.28) 67.2 12.2 0.016 5,108 85.7-96.9 0.57 0.019 (0.033) 0 2.2 0.70 
Exome-array 43,421 89 1.1x10-5 1.12 (1.07-1.17) 2.8 9.3 0.41 24,031 88.6 0.0090 0.019 (0.007) 0 5.4 0.86 
Combined 56,339 86.6-97.6 4.0x10-9 1.13 (1.09-1.18) 68.1 12.6 0.014 29,139 85.7-96.9 0.0084 0.034 (0.013) 0 2.5 0.78 
Ser1554Tyr (rs35742417) 
Within-
ancestry 
African Americans 2,074 78.8 0.87 0.98 (0.83-1.13) - - - 508 79.3 0.87 0.012 (0.076) - - - 
East Asians 2,165 96.6 0.89 0.97 (0.64-1.31) - - - 1,104 96.6 0.91 -0.013 (0.120) - - - 
Europeans 4,541 82.3 0.023 1.12 (1.01-1.23) - - - 2,144 80.9 0.28 0.042 (0.039) - - - 
Hispanics 1,943 92.4 0.30 1.11 (0.87-1.35) - - - 844 92 0.19 0.110 (0.087) - - - 
South Asians 2,217 94.4 0.58 1.07 (0.81-1.33) - - - 508 93.2 0.89 0.018 (0.120) - - - 
Meta-
analysis 
Exome sequence 12,918 78.8-96.6 0.065 0.94 (0.86-1.02) 0 3.2 0.53 5,108 80.9-96.6 0.17 0.041 (0.030) 0 1.1 0.90 
Exome-array 69,867 79.7 0.00029 1.05 (1.02-1.08) 21.4 15.3 0.23 33,230 78.9 8.4x10-9 0.024 (0.004) 0 12.3 0.51 
Combined 82,784 78.8-96.6 4.9x10-5 1.05 (1.02-1.08) 0 1.5 0.83 38,338 80.9-96.6 2.7x10-9 0.053 (0.009) 0 1.3 0.94 
 
Neff: effective sample size. EAF: effect allele frequency. OR: odds-ratio. CI: confidence interval. I2: heterogeneity measure in %. p_het: p-value for Cochran’s Q statistic. N: number of individuals analysed. 𝛽: 
regression coefficient estimates. SE: standard error.  
Summary statistics of just the two coding variants showing significant association signals for either T2D or fasting glucose have been summarized.   
For Supplementary Table 20 see Excel File “20Supp20 - T2D loci and genes.xlsx” 
  
 Supplementary Table 21 | Characterization of role of coding variants within genes in established common variant GWAS regions through reciprocal conditional analysis.  
Locus Variant 
Combined 
exomes 
p-value 
Coding variant(s) GWAS variant 
Comments Variant Conditioned on Unconditional p-value 
Conditional 
p-value Variant Conditioned on 
Unconditional 
p-value 
Conditional 
p-value 
THADA 
Cys1605Tyr 3.3x10-10 Cys1605Tyr 
unconditioned 0.00035  rs10203174 unconditioned 5.7x10-6  The previously reported non-coding GWAS SNP 
(or a close proxy) at the THADA locus is not 
available on the exome array, so approximate 
conditional analyses were undertaken in GCTA in 
a genome-wide imputed meta-analysis from the 
GoT2D Consortium (METHODS). Association 
signals for THADA Cys1605Tyr and the GWAS 
SNP at this locus are partially correlated. The 
association signal for the GWAS SNP is not 
entirely extinguished in reciprocal conditional 
analysis.  However, the association signals for 
THADA Thr1187Ala and the GWAS SNP at this 
locus are indistinguishable from each other in 
reciprocal conditional analysis.  THADA is a 
candidate effector transcript for the non-coding 
GWAS signal at this locus. 
rs10203174  0.92  Cys1605Tyr  0.0063 
Thr1187Ala  0.81     
Thr1187Ala 1.3x10-5 Thr1187Ala 
unconditioned 5.8x10-6  rs10203174 unconditioned 5.7x10-6  
rs10203174  0.37  Thr1187Ala  0.46 
Cys1605Tyr  0.0053     
TSPAN8 Ser213Ala 2.7x10-6 Ser213Ala 
unconditioned 3.5x10-5  rs4760790 unconditioned 8.6x10-6  
Association signals for TSPAN8 Ser231Ala and 
the GWAS SNP at this locus are partially 
correlated. The association signal for the GWAS 
SNP is not entirely extinguished in reciprocal 
conditional analysis. TSPAN8 is a candidate 
effector transcript at this locus. 
rs4760790  0.00024  Ser213Ala  0.0025 
HNF4A Thr139Ile 2.9.x10-6 Thr139Ile 
unconditioned 9.5x10-7  rs4812831 unconditioned 4.7x10-5  Association signals for HNF4A Thr139Ile and the 
GWAS SNP at this locus are independent of 
each other. The association signal for the GWAS 
SNP is not extinguished in reciprocal conditional 
analysis. Previous GWAS signal is not mediated 
through HNF4A Thr139Ile. 
rs4812831  4.0x10-7  Thr139Ile  2.4x10-5 
rs10842994  0.18  Gly43Arg  7.7x10-5 
 
Combined exomes p-values are derived from the meta-analysis of sequence and array datasets, with total sample size up to 92,794 (34,809 cases, 57,985 controls: effective sample size 82,758). Conditional analysis was performed 
only on the exome-array component (28,305 cases, 51,549 controls: effective sample size 69,866). However, the previously reported non-coding GWAS SNP at the THADA locus (rs10203174) is not available on the exome array; p-
values reported here come from approximate conditional analyses undertaken in GCTA in a genome-wide imputed meta-analysis from the GoT2D Consortium (METHODS). We also examined genome-wide sequence and imputed 
data sets from the GoT2D consortium (N=2,657; METHODS) to determine whether these causal inferences were robust to more comprehensive coverage of regional variation. 
Supplementary Table 22 | List of monogenic analysis categories and genes
Monogenic ALL Monogenic PRIMARY Monogenic OMIM
ABCC8 ABCC8 ABCC8
AGPAT2
AIRE
AKT2
ALMS1 ALMS1
ARL6
BBS1
BBS10
BBS12
BBS2
BBS4
BBS5
BBS7
BBS9
BLK BLK
BSCL2
CAV1
CEL CEL CEL
CEP290
CFTR
CIDEC
CISD2 CISD2
DCAF17
DMPK
EIF2AK3 EIF2AK3
FOXP3
GATA4 GATA4
GATA6 GATA6
GCK GCK GCK
GLIS3 GLIS3
GLUD1 GLUD1
HADH HADH
HNF1A HNF1A HNF1A
HNF1B HNF1B HNF1B
HNF4A HNF4A HNF4A
INS INS INS
INSR INSR
ISL1
ITER3IP1
KCNJ11 KCNJ11 KCNJ11
KLF11 KLF11
LEP
LEPR
LMNA LMNA
MC4R
MKKS
MKS1
MNX1 MNX1
NEUROD1 NEUROD1 NEUROD1
NEUROG3 NEUROG3
PAX4 PAX4
PAX6
PCNT
PCSK1
PDX1 PDX1 PDX1
PIK3CA
PIK3R1
PLAGL1
PLIN1
POLD1
POMC
PPARG PPARG
PPP1R3A
PRSS1
PTEN
PTF1A PTF1A
PTRF
RFX6 RFX6
SH2B1
SIRT1
SLC16A1
SLC19A2
SLC2A2 SLC2A2
SPINK1
TRIM32
TTC8
UCP2 UCP2
WFS1 WFS1
WRN
ZFP57
ZMPSTE24
Supplementary Figure 23 | Age of diagnosis of variant carriers. To assess whether individuals 
carrying variants in genes for monogenic forms of diabetes were enriched for patients with 
undiagnosed monogenic diseases, we examined the ages of diagnosis for carriers and compared 
them to those of non-carriers. As some diseases typically manifest at an earlier age than does T2D 
(e.g. MODY), a lower age of diagnosis for carriers might suggest that the monogenic phenotype, 
rather than late-onset T2D, is responsible for the diabetes phenotype in carriers. Shown is the mean 
age of diagnosis for carriers of variants in (a) the Monogenic All gene set, (b) the Monogenic Primary 
gene set, and (c) the Monogenic OMIM gene set. In each case, the mean ages are computed for 
carriers of variants in each of the five variant masks discussed in the text. Error bars indicate one 
standard deviation. Numbers of carriers and non-carriers for each mask are listed in parentheses at 
the bottom of the plot. 
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Supplementary Figure 24 | Accumulation of ultra-rare deleterious alleles amongst 
genes contributing to pre-specified “biologically-driven” gene-sets. a, Using the SMP 
approach, we confirmed association in the ‘Monogenic All” gene set (81 genes: p= 0.006, 
OR=1.35 for singletons; p=0.04, OR=1.07 for ultra-rare alleles) and the “Monogenic OMIM” 
gene set (13 genes: p=0.0088, OR=2.4 for singletons; p=0.02, OR=1.82 for ultra-rare alleles). 
We also detected a separate “burden” signal for increased T2D-risk attributable to singleton 
alleles within the MTOR pathway (p=0.012, OR=3.61). b, Individual gene-ranking of 
composite set genes (set genes with p< .05 are shown). Genes are ranked by their case 
burden of rare PTVs, from top to bottom, for the Mtor and the monogenic all gene sets 
(labeled MTOR and MODY ALL, respectively). The squares along the bottom indicate to 
which sets each gene belongs. The red and blue triangles represent case and control counts 
for each gene. The lines represent the statistical significance of the best test for this set: that 
is, the significance of the top K genes, evaluated by permutation. For example, the drivers of 
the MTOR pathway signal include three case-only PTV singletons in both MNK1 and MTOR. 
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Supplementary Table 25 | All pathway enrichment signals with uncorrected FDR <= 10% from 
gene-set enrichment analyses conducted on the ancestry-specific and combined exome sequence 
data. Ancestries are denoted as European (EUR), East Asian (EA), South Asian (SA), Hispanic (HS) and 
African American (AA).  For hand-curated gene-sets see Supplementary Table 32. We detected no 
study-wide significant signals (defined FDR < 5% after correction for multiple testing on four masks and 
five gene set collections). However, we detect nominal associations (uncorrected FDR <= 10%) in a 
subset of analyses, as listed below.  
 
Mask Ancestry GeneSet FDR 
PTV+NSbroad Combined Transport of organic anions (Reactome) 1.1% 
PTV+missense AA Cytosolic DNA sensing pathway (Kegg) 1.4% 
PTV+NSstrict HS Glycosaminoglycan biosynthesis chondroitin sulphate (Kegg) 3.1% 
PTV only HS TRIF-mediated TLR3 signaling  (Reactome) 3.5% 
PTV+NSstrict SA Secretory granule (Gene Ontology) 3.6% 
PTV+NSbroad AA Riboflavin metabolism (Kegg) 4.9% 
PTV+NSbroad Combined Mendelian: long qt syndrome (hand curated) 5.1% 
PTV only EA Fatty acid metabolism (Kegg) 5.7% 
PTV+NSstrict EUR Mismatch repair (Kegg) 5.7% 
PTV+NSbroad Combined Mendelian: immune (hand curated) 5.8% 
PTV+NSstrict EA Beta alanine metabolism (Kegg) 6.4% 
PTV only AA Tak1 activates NFKB by phosphorylation and activation of 
IKKS complex (Reactome) 
6.9% 
PTV+NSbroad HS ABC transporters (Kegg) 7.5% 
PTV+NSbroad Combined Cellular polysaccharide metabolic process (Gene Ontology) 8.4% 
PTV+NSstrict EA Limonene and pinene degradation (Kegg) 8.6% 
PTV+NSbroad EA Integrin signaling (MSigDb Canonical Pathway) 8.9% 
PTV+NSstrict AA Triggering pathway mediating stimulation of insulin secretion 
(hand-curated) 
9.5% 
PTV+NSstrict AA Lysine degradation (Kegg) 10.0% 
 
Supplementary Figure 26 | PPI analyses.  A, QQ-plot of Fisher aggregated empirical p-
values (“PTV+NSstrict” mask) from the 2418 clusters generated by clusterONE based on 
100,000 iterations. Cluster 630, consisting of ASB (ankyrin repeat and SOC box protein) 
protein family members interacting with RNF7 and CUL5, showed the strongest enrichment 
(“PTV+NSstrict” mask, empirical p-value P=5x10-5); B, Membership of the cluster 630 sub-
network highlighted by the clusterONE analyses.  ASB6 is adipocyte-specific and interacts 
with APS to enable recruitment of elongins to the insulin receptor-signaling complex; C, PPI 
sub-network constructed using the top 15 modules generated with dmGWAS from gene-
based association p-values derived using the “PTV+NSstrict” variant mask. The sub-network 
includes the cluster of ASB proteins found in the clusterONE method as significant (cluster 
630, shaded area), a cluster of mitochondrial-activity related genes, and the PAM gene; D, 
PPI sub-network built using the 15 top modules generated with dmGWAS from gene-based 
association p-values derived using the “PTV+NSbroad” mask.  The sub-network includes PAM 
and FES, both of which contain exome-wide significant coding variants associated with T2D.  
The darkness of the node in the sub-networks is proportional to its p-value (lighter color 
indicates lower p-values) and the thickness of the edge is proportional to confidence score for 
the interaction between each pair of proteins. 
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Supplementary Figure 27 | Use of permutations to evaluate synthetic association hypothesis at 10 T2D 
GWAS loci.  
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Supplementary Table 28 | Properties of credible sets constructed at all T2D GWAS loci. Loci are sorted by 
the size of the final 99% credible set (from smallest to largest; column 5 below). Up to 2 credible sets were 
constructed for independent signals (r2<0.1) at all previously known autosomal T2D GWAS loci. Only loci where 
the index SNV had MAF>1% in the GoT2D sequencing data were included; RBM43 and SGCG were excluded 
due to low index SNV MAF. CILP2 was excluded due to poor sequencing quality across this region in the GoT2D 
experiment. At loci where the two independent signals have opposite directions of effect at the minor allele (risk, 
protective), the credible sets are labeled as such (“risk”, “prot”); at loci where both signals are in the same 
direction, they are labeled “sig1” and “sig2”. 
 
Locus 
# candidate 
variants 
with r2>0.1 
to GWAS 
tag 
# 
indels 
# imputed 
with low 
quality 
# 
variants 
in 99% 
credible 
set 
# missense 
variants in 
credible 
set 
% 
variants 
in 1000G 
% 
variants 
in 
HapMap 
Post. 
prob. of 
top 5 
variants 
Post. 
prob. of 
top 10 
variants 
CDKN2AB_risk 16 0 1 2 - 100% 50% 1.00 1.00 
TCF7L2 121 8 0 3 - 100% 33% 1.00 1.00 
CCND2 27 4 1 4 - 100% 25% 0.99 0.99 
ZBED3 99 2 0 5 - 100% 60% 0.99 0.99 
KCNQ1_sig2 59 4 0 5 - 100% 40% 1.00 1.00 
SLC30A8 57 3 0 7 1 100% 43% 0.93 0.99 
CDKAL1 376 33 1 9 - 100% 56% 0.74 1.00 
CDKN2AB_prot 27 0 2 12 - 100% 42% 0.75 0.96 
HHEX 236 23 2 14 - 100% 43% 0.47 0.79 
BCL11A 189 16 0 15 - 100% 73% 0.76 0.96 
ST6GAL1 46 1 1 19 - 100% 42% 0.66 0.92 
HNF1B 40 2 4 21 - 100% 48% 0.80 0.92 
ADCY5 200 20 3 22 - 100% 41% 0.71 0.86 
JAZF1 171 13 2 25 - 88% 40% 0.52 0.80 
ADAMTS9 133 8 0 26 - 100% 62% 0.49 0.79 
TLE1 185 18 1 26 - 100% 42% 0.86 0.94 
GCK 29 2 0 28 - 100% 57% 0.49 0.61 
DUSP8 110 10 4 28 - 93% 36% 0.58 0.81 
PROX1 88 7 0 29 - 93% 59% 0.57 0.82 
BCAR1 616 42 13 30 - 90% 10% 0.66 0.83 
ZMIZ1 164 8 2 33 - 100% 70% 0.54 0.82 
BCL2 35 1 0 35 - 97% 69% 0.56 0.64 
KCNQ1_sig1 83 2 35 40 - 98% 18% 0.72 0.76 
TSPAN8 201 15 2 41 - 95% 54% 0.73 0.94 
SPRY2 206 14 0 42 - 95% 43% 0.54 0.95 
LAMA1 56 3 3 45 - 96% 62% 0.25 0.44 
ANK1 176 17 0 48 - 96% 35% 0.37 0.65 
IGF2BP2 121 11 1 50 - 96% 40% 0.17 0.29 
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CENTD2 311 23 4 53 - 94% 23% 0.38 0.71 
PTPRD 55 5 1 54 - 96% 35% 0.26 0.37 
PRC1 260 27 1 62 1 94% 45% 0.32 0.50 
HMGA2 209 13 3 67 - 94% 48% 0.38 0.68 
LPP 121 11 0 70 - 96% 49% 0.71 0.79 
SLC16A13 78 5 10 71 5 99% 30% 0.15 0.28 
KLHDC5 212 27 0 72 - 94% 26% 0.28 0.48 
CDC123 170 16 7 74 - 99% 32% 0.64 0.88 
FTO 144 4 1 80 - 100% 41% 0.30 0.48 
MTNR1B 91 7 1 81 - 93% 37% 0.48 0.56 
UBE2E2 507 37 1 84 - 98% 30% 0.37 0.68 
IRS1 403 37 0 90 - 99% 49% 0.16 0.28 
ARL15 245 25 0 92 - 93% 28% 0.10 0.18 
KLF14 98 8 1 93 - 98% 34% 0.09 0.17 
RASGRP1 96 6 2 93 - 100% 45% 0.22 0.32 
DGKB_prot 154 8 5 101 - 98% 53% 0.17 0.31 
C2CD4 229 9 0 102 - 99% 60% 0.18 0.31 
MC4R_prot 146 12 17 107 1 98% 14% 0.12 0.23 
PAX4_prot 115 6 2 111 - 97% 31% 0.14 0.23 
TMEM154 135 10 8 113 - 96% 53% 0.28 0.39 
KCNK16 119 11 0 117 3 99% 49% 0.11 0.20 
PPARG 306 28 1 123 1 95% 33% 0.12 0.20 
NOTCH2 137 11 3 128 2 96% 52% 0.24 0.30 
HNF4A 202 18 0 139 - 96% 34% 0.74 0.85 
GLIS3 145 6 0 139 - 98% 57% 0.19 0.30 
ZFAND6 165 15 0 144 - 97% 33% 0.24 0.36 
WFS1 210 16 1 145 2 93% 39% 0.24 0.36 
GRK5 148 14 0 146 - 97% 51% 0.18 0.27 
ANKRD55 181 7 0 148 - 100% 31% 0.27 0.47 
VPS26A 152 12 0 150 - 97% 35% 0.07 0.12 
GIPR 238 18 1 151 2 96% 21% 0.82 0.83 
AP3S2 186 18 8 161 - 98% 39% 0.15 0.25 
DGKB_risk 199 13 3 166 - 97% 46% 0.51 0.73 
GRB14 177 17 1 170 1 99% 51% 0.19 0.34 
PEPD 316 30 0 194 - 98% 30% 0.43 0.72 
GPSM1 223 17 26 220 5 96% 40% 0.06 0.09 
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TLE4 326 21 13 224 - 99% 50% 0.19 0.32 
MC4R_risk 388 33 0 250 - 97% 50% 0.10 0.19 
RBMS1 313 16 0 250 - 97% 45% 0.23 0.31 
SSR1 313 38 0 256 2 97% 22% 0.10 0.19 
CTBP1 279 20 23 263 1 95% 13% 0.15 0.26 
MACF1 429 37 8 305 1 94% 30% 0.13 0.18 
HMG20A 955 68 0 319 - 97% 44% 0.10 0.17 
THADA 592 41 5 319 3 97% 39% 0.07 0.12 
HNF1A 516 45 1 366 3 95% 35% 0.42 0.56 
KCNJ11 528 50 1 398 4 96% 36% 0.52 0.75 
MPHOSPH9 477 39 57 437 1 96% 32% 0.03 0.05 
ZFAND3 466 44 6 447 - 99% 25% 0.09 0.12 
GCKR 468 51 1 451 8 96% 43% 0.24 0.27 
SRR 463 34 0 457 5 98% 43% 0.11 0.14 
TP53INP1 696 53 0 502 - 97% 36% 0.16 0.24 
FAF1 839 75 10 773 1 97% 18% 0.19 0.20 
TMEM163 887 83 37 835 1 96% 43% 0.20 0.28 
PAX4_risk 857 87 0 844 1 96% 49% 0.03 0.05 
POU5F1 1782 74 1 993 14 96% 37% 0.24 0.30 
 Averages 97% 41%  
 
Supplementary Figure 29 | Trans-ethnic principal component analysis for exome-sequence 
samples. African American studies (N=2,074): Jackson Heart Study (AJ) and Wake Forest School of 
Medicine Study (AW); East Asian studies (N=2,165): Korea Association Research Project (EK) and 
Singapore Diabetes Cohort Study and Singapore Prospective Study Program (ES); Hispanic studies 
(N=1,943): San Antonio Family Heart Study (HA) and Starr County (HS); South Asian studies 
(N=2,217): London Life Sciences Population Study (SL) and Singapore Indian Eye study (SS); and 
European studies (N=4,541): Ashkenazi (UA), Metabolic Syndrome in Men Study (UM), and GoT2D 
study (GO). A total of 10,348 independent QC passed, autosomal variants (trans-ethnic r2<0.05) with 
MAF>1% in all ancestry groups were considered for constructing axes of genetic variation through 
principal components analysis implemented in EIGENSTRAT to identify ethnic outliers. 
 
  
Supplementary Table 30 | Summary of samples and adjustments for EMMAX and WALD single-
variant association analysis for 12,940 exome-sequence samples. Genomic control inflation 
factors (λ) were calculated on the basis of independent autosomal variants with MAF>1% within each 
ancestry group. 
Ancestry group 
 
EMMAX WALD  
N λ  N PCs used for adjustment λ  
African American 2,074 1.00 2,025 PC1 1.01 
East Asian 2,165 1.02 2,164 PC1 1.02 
European 4,541 0.99 4,518 PC1 - PC4 1.07 
Hispanic 1,943 1.00 1,938 PC1 - PC4 1.03 
South Asian 2,217 1.03 2,199 PC1 1.05 
N: total number of samples. PC: principal component. 
Supplementary Figure 31 | Global ancestry estimates for 1,943 Hispanic samples. 
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EIF2AK3 ERN1 ATF6 CCDC88B EIF2S1 XBP1 ATF4 ATF5 PPP1R15A DDIT3 BCL2 MAPK8 
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Diabetes_McGill_Inflamatory_Cytokines Diabetes_McGill_Inflamatory_Cytokines
AGT GPR77 CCR2 CCR5 CD74 CHUK CRADD CXCR1 CXCR2 CXCR3 CXCR4 ECSIT 
FADD FGF21 FGFR1 FGFR2 FGFR3 IKBKB IKBKE IKBKG IL10 IL10RA IL10RB IL13 
IL13RA1 IL13RA2 IL1B IL1R1 IL6 IL6R IL6ST IL8 IRAK1 IRAK2 JAK1 JAK2 JAK3 KDR KLB 
LAP3 LTBP1 LTBP2 LTBP3 LTBP4 MADD MAP2K1 MAP2K2 MAP3K1 MAP3K14 MAP4K1 
MAPK14 MAPK8 CCL2 NAMPT NFKB1 NFKBIA NMNAT1 NMNAT2 NMNAT3 PIK3C2A 
PIK3C2B PIK3CA RHOA RIPK1 RIPK2 RIPK3 RIPK4 SHC1 SHC2 SIRT1 SIRT2 SIRT3 
SIRT4 SIRT5 SIRT6 SIRT7 SMAD2 SMAD3 SMAD4 SMAD6 SMAD7 STAT3 TAB1 MAP3K7 
TGFB1 TGFB2 TGFB3 LEFTY2 TGFBR1 TGFBR2 TNF TNFRSF1A TNFRSF1B TOLLIP 
TRADD TRAF2 TRAF6 TYK2 VEGFA XIAP
Diabetes_McGill_Insulin Diabetes_McGill_Insulin
STX1A STX1B SNAP25 VAMP2 SYT7 SYT5 SENP1 ATF6 XBP1 ERN1 EIF2AK3 ATF4 
EIF2A
Diabetes_McGill_Leptin_Pathway Diabetes_McGill_Leptin_Pathway MAPK1 MAPK3 GRB2 IRS1 JAK1 JAK2 LEP LEPR PTPN11 SOCS3 STAT3 STAT5A
Diabetes_McGill_Mtor_pathway Diabetes_McGill_Mtor_pathway
AKT1 EIF3A EIF4A1 EIF4A2 EIF4B EIF4E EIF4EBP1 EIF4G1 EIF4G2 EIF4G3 FKBP1A 
MKNK1 MTOR PDK2 PDPK1 PIK3CA PIK3R1 PPP2CA PTEN RPS6 RPS6KB1 TSC1 TSC2
Diabetes_McGill_RAS Diabetes_McGill_RAS
DIRAS1 DIRAS2 DIRAS3 ERAS GEM HRAS KRAS MRAS NKIRAS1 NKIRAS2 NRAS RALA 
RALB RAP1A RAP1B RAP2A RAP2B RAP2C RASD1 RASD2 RASL10A RASL10B RASL11A 
RASL11B RASL12 REM1 REM2 RERG RERGL RRAD RRAS RRAS2 RASSF1 RASSF2 
RASSF3 RASSF4 RASSF5 RASSF6 RASSF7 RASSF8 RASSF9 RASSF10
Diabetes_McGill_Triggering_pathway_mediating_sti
mulation_of_insulin_secretion
Diabetes_McGill_Triggering_pathway_mediating_sti
mulation_of_insulin_secretion
SLC2A1 SLC2A3 GCK PKLR PKM2 DLAT DLD PDHA1 PDHB PDHX PDP1 CS ACO1 ACO2 
IDH2 OGDH DLST SUCLA2 SUCLG1 SUCLG2 SDHA SDHB SDHC SDHD FH MDH1 MDH2
Diabetes_McGill_Wnt_pathway Diabetes_McGill_Wnt_pathway
APC AXIN1 BTRC CCND1 CREBBP CSNK1A1 CSNK1D CSNK2A1 CTBP1 CTNNB1 DVL1 
FRAT1 FZD1 GSK3B HDAC1 LEF1 MAP3K7 MYC NLK PPARD PPP2CA SMAD4 TAB1 
TLE1 WIF1 WNT1
Mendelian_Blood_Desease Mendelian_Blood_Desease
ITGB2 FERMT3 SLC35C1 HBA1 HBA2 HBB RPL11 RPL35A RPL26 RPL5 RPS10 RPS17 
RPS17L RPS19 RPS24 RPS26 RPS7
Mendelian_Cerebral_Degeneration_Due_to_Genera
lized_Lipidoses
Mendelian_Cerebral_Degeneration_Due_to_Genera
lized_Lipidoses
GLA NPC1 NPC2 SMPD1 GBA SLC37A4 GAA AGL PYGM PHKA1 PHKA2 PHKB PHKG2 
LAMP2 PGAM2
Mendelian_Disorders_of_Copper_Metabolism Mendelian_Disorders_of_Copper_Metabolism ATP7A ATP7B PRNP
Mendelian_Disorders_of_Fatty_Acid_Oxidation Mendelian_Disorders_of_Fatty_Acid_Oxidation ETFA ETFB ETFDH CPT2 ACADSB ACADVL CPT1A HADHA SLC25A20 ACADM
Supplementary Table 32 | Premium gene sets
Mendelian_Etc Mendelian_Etc HTT GFAP ARSA PSAP GALC SCN9A FXN MEFV SAA1 AR MEN1 RET
Mendelian_Hereditary_Sensory_Neuropathy Mendelian_Hereditary_Sensory_Neuropathy
NTRK1 PMP22 MPZ LITAF EGR2 NEFL MFN2 KIF1B RAB7A LMNA TRPV4 BSCL2 GARS 
HSPB1 GDAP1 HSPB8 DNM2 MTMR2 SBF2 SH3TC2 NDRG1 PRX FGD4 FIG4 YARS GJB1 
PRPS1 MED25 INF2 KARS
Mendelian_Immune Mendelian_Immune AIRE CD40LG FAS FASLG CYBB CYBA NCF1 NCF2 NCF4
Mendelian_Long_QT_syndrome Mendelian_Long_QT_syndrome KCNQ1 KCNH2 KCNE1 KCNE2 CACNA1C CAV3 SCN5A SCN4B
Mendelian_Metabolism Mendelian_Metabolism
SLC22A5 APRT HPRT1 UMPS SLC25A15 NAGS CPS1 ASS1 ASL ARG1 CLCN5 DMP1 
ENPP1 FGF23 PHEX SLC34A3 CYP27B1 ABCA1 APOA1 LPL APOB MTTP SAR1B LCAT 
GCDH PSPH DHTKD1 AHCY GNMT MAT1A GATM GLDC G6PD
Mendelian_Severe_Combined_Immunodeficiency Mendelian_Severe_Combined_Immunodeficiency
IL2RG JAK3 ADA RAG1 RAG2 ZAP70 PNP NHEJ1 IL7R CD3D DCLRE1C PTPRC RFX5 
RFXANK RFXAP AK2 CIITA
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